
<html lang="en"     class="pb-page"  data-request-id="28424ee5-aa9e-46c6-bf64-791a5825707e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2015.58.issue-9;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm501464c;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Minsoo  Song" /></meta><meta name="dc.Description" content="A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2% of lung adenocarcinomas (LADCs) in late 2..." /></meta><meta name="Description" content="A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2% of lung adenocarcinomas (LADCs) in late 2..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 4, 2015" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501464c" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501464c" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501464c" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501464c" /></link>
        
    
    

<title>Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501464c" /></meta><meta property="og:title" content="Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0008.jpeg" /></meta><meta property="og:description" content="A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2% of lung adenocarcinomas (LADCs) in late 2011. Several related clinical trials for non-small-cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of these known RET tyrosine kinase inhibitors (TKIs) for KIF5B-RET fusion-positive NSCLC are discussed. A kinase inhibitor that can target a driver mutation specifically may lead to a superior clinical benefit compared with broad-spectrum kinase inhibitors. In this regard, an analysis of the structure of RET kinase and its complex with known RET inhibitors are also briefly discussed." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501464c"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501464c">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501464c&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501464c&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501464c&amp;href=/doi/10.1021/jm501464c" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 3672-3681</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501459c" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.5b00127" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Minsoo++Song">Minsoo Song</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Cheombok-ro, Dong-gu, Daegu 701-310, Korea</span></div><div class="corresp-info"><strong>*</strong>Phone: +82 53 790 5213. Fax: +82 53 790 5219. E-mail: <a href="/cdn-cgi/l/email-protection#0e637d6160694e6a69636768207c6b20657c"><span class="__cf_email__" data-cfemail="2a475945444d6a4e4d47434c04584f044158">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501464c&amp;href=/doi/10.1021%2Fjm501464c" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 3672–3681</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 27, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 September 2014</li><li><span class="item_label"><b>Published</b> online</span>4 February 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501464c" title="DOI URL">https://doi.org/10.1021/jm501464c</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3672%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMinsoo%2BSong%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D9%26contentID%3Djm501464c%26title%3DProgress%2Bin%2BDiscovery%2Bof%2BKIF5B-RET%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small-Cell%2BLung%2BCancer%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3681%26publicationDate%3DMay%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501464c"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3654</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">32</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501464c" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Minsoo&quot;,&quot;last_name&quot;:&quot;Song&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;3672-3681&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501464c&quot;},&quot;abstract&quot;:&quot;A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2% of lung adenocarcinomas (LADCs) in late 2011. Several related clinical trials for non-small-cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of these known RET tyrosine kinase inhibitors (TKIs) for KIF5B-RET fusion-positive NSCLC are discussed. A kinase inhibitor that can target a driver mutation specifically may lead to a superior clinical benefit compared with broad-spectrum kinase inhibitors. In this regard, an analysis of the structure of RET kinase and its complex with known RET inhibitors are also briefly discussed.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501464c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501464c" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501464c&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501464c" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501464c&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501464c" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501464c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501464c&amp;href=/doi/10.1021/jm501464c" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501464c" /></input><a href="/doi/pdf/10.1021/jm501464c" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501464c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501464c%26sid%3Dliteratum%253Aachs%26pmid%3D25625428%26genre%3Darticle%26aulast%3DSong%26date%3D2015%26atitle%3DProgress%2Bin%2BDiscovery%2Bof%2BKIF5B-RET%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small-Cell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D9%26spage%3D3672%26epage%3D3681%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291864" title="Fluorescence resonance energy transfer">Fluorescence resonance energy transfer</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jmcmar.2015.58.issue-9/20150514/jmcmar.2015.58.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2% of lung adenocarcinomas (LADCs) in late 2011. Several related clinical trials for non-small-cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of these known RET tyrosine kinase inhibitors (TKIs) for KIF5B-RET fusion-positive NSCLC are discussed. A kinase inhibitor that can target a driver mutation specifically may lead to a superior clinical benefit compared with broad-spectrum kinase inhibitors. In this regard, an analysis of the structure of RET kinase and its complex with known RET inhibitors are also briefly discussed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div id="ac_i1" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i1"> </h2><div class="NLM_p"><b>Lung cancer</b> is the leading cause of cancer-related mortality in the world. More than 1.8 million patients were diagnosed with lung cancer worldwide, and it comprised 13% of all new cancer cases diagnosed in 2012. This number is expected to increase and produce a higher cancer burden worldwide as a result.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Lung cancer is classified as small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC). NSCLC is any type of epithelial lung cancer other than SCLC, and it accounts for 85% of lung cancers in western countries.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The most common types of NSCLC include squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, based on histological types. Although NSCLCs are associated with cigarette smoke, adenocarcinomas may be found in those who never smoked. In the United States alone, the 5-year relative survival rate from 2003 to 2009 for patients with lung cancer was 17%, and for the subclasses of lung cancer, the 5-year survival rate was even lower: 6% for small-cell lung cancer and 18% for non-small-cell lung cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In 2014, 224 210 of the estimated new cases and 159 260 of the deaths from lung cancer (NSCLC and SCLC combined), accounting for approximately 27% of all cancer deaths, are expected to occur in the United States.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Treatments for lung cancer include surgery, radiation therapy, chemotherapy, and targeted therapies. NSCLCs are relatively insensitive to chemotherapy and radiation therapy compared with SCLCs. For early stage NSCLCs, surgery is usually the treatment of choice. For patients with unresectable disease, local control can be achieved with radiation therapy combined with chemotherapy, targeted drugs, or some combination, but cure is limited only to a small number of patients.</div><div class="NLM_p">Monoclonal antibodies and small-molecule tyrosine kinase inhibitors (TKI) are two types of targeted therapy being used in the treatment of NSCLC. Monoclonal antibody therapies include bevacizumab (Avastin), a vascular endothelial growth factor (VEGF) inhibitor, and cetuximab (Erbitux), an epidermal growth factor receptor (EGFR) inhibitor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Bevacizumab binds to vascular endothelial growth factor (VEGF) and prevents angiogenesis, the growth of new blood vessels, which tumors need for growth. Cetuximab binds to the epidermal growth factor receptor (EGFR) and works by stopping cancer cells from growing and dividing. Over the past 20 years, numerous small-molecule tyrosine kinase inhibitors (TKI) have been rigorously developed to treat NSCLC (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Two major categories of targeted small-molecule TKIs include vascular endothelial growth factor (VEGF) directed and epidermal growth factor receptor (EGFR) directed therapies, as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Most of these are reversible small-molecule TKIs that block autophosphorylation and substrate phosphorylation in an ATP-competitive manner in general, thereby preventing oncogenic activity. In the case of the irreversible inhibitor afatinib, it is known that the thiol of Cys<sup>797</sup> makes a covalent bond by addition to the α,β-unsaturated ketone of afatinib in a 1,4-addition fashion (Michael addition) at the ATP binding site and inhibits EGFR more potently than the reversible inhibitors do.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Among these small-molecule inhibitors, the EGFR TKIs and crizotinib have shown better efficacy in tumors harboring sensitizing EGFR mutations or ALK translocations, whereas VEGF TKIs showed much less efficacy in NSCLC. It is noteworthy that ceritinib was approved by the FDA in early 2014 for patients with crizotinib-resistant NSCLC, just 2 years after crizotinib’s fast track approval by the FDA.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> It is reported that more than 50% of lung adenocarcinomas (LADC) have critical driver mutations in oncogenes which potentiate tumor proliferation and spread.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Such driver mutations commonly occur in KRAS, EGFR, ALK, HER2, and others. Recent achievements in the improvement of tumor regression and prolonged survival with small-molecule EGFR TKIs and crizotinib clearly suggest that the development of novel agents for newly evolving driver mutations may achieve successful targeting and lead to better outcomes in treating NSCLCs.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Representative Targeted Therapies for the Treatment of NSCLC Approved by the U.S. FDA</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">monoclonal antibody</th><th class="colsep0 rowsep0" align="center">small-molecule TKIs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGF-targeted</td><td class="colsep0 rowsep0" align="left">bevacizumab</td><td class="colsep0 rowsep0" align="left">sorafenib, sunitinib, vandetanib, motesanib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR-targeted</td><td class="colsep0 rowsep0" align="left">cetuximab</td><td class="colsep0 rowsep0" align="left">erlotinib, gefitinib, afatinib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">others</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">crizotinib (EML4-ALK), ceritinib (ALK+, crizotinib resistant)</td></tr></tbody></table></div></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Small-molecule TKIs for NSCLC approved by the U.S. FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">KIF5B-RET</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Between late 2011 and early 2012, a new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was first identified as a new driver mutation in NSCLC by four independent research groups simultaneously.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> For example, Kohno et al. identified the four fusion variants of KIF5B-RET that contained the KIF5B coiled-coil domain in various lengths and the fully retained RET kinase domain as a major component using whole transcriptome sequencing. It was likely that aberrant activation of the kinase function of RET was initiated by homodimerization by the KIF5B coiled-coil domain.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> A simplified schematic representation of KIF5B, RET proteins, and KIF5B-RET fusions is depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. Rearranged during Transcription (RET) is a transmembrane receptor tyrosine kinase (RTK). The extracellular portion contains four cadherin-like domains (CLD), a single Ca<sup>2+</sup> binding site between CLD2 and CLD3, and a cysteine-rich domain (CRD). The intracellular portion contains the juxtamembrane domain and the core kinase domain. RET activation involves glial-derived neurotrophic factor (GDNF) family ligands and a co-receptor, glial-derived neurotrophic factor family receptor α1 (GFR-α), to trigger autophosphorylation on intracellular tyrosine residues and stimulate multiple downstream signaling pathways, including RAS-MAPK, PI3K-AKT, PKC, and JAK-STAT.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Traditionally, it has been thought that point mutations in the RET gene are associated with thyroid cancers, including multiple endocrine neoplasia 2 syndromes (MEN2A and MEN2B), familial medullary thyroid carcinoma (FMTC), and RET fusions, such as CCDC6 and others related to papillary thyroid carcinoma (PTC).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Three RET kinase inhibitors, vandetanib, cabozantinib, and sorafenib, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of thyroid cancer. However, the clinical activity of RET kinase inhibitors in RET fusion-positive thyroid cancers has not been fully investigated.</div><div class="NLM_p">In this regard, discovery of the KIF5B-RET fusion gene is particularly important. The RET fusion gene was only found in 1–2% (6–19% for tumors without other genetic variants) of lung adenocarcinomas (LADCs) from both Asians and non-Asians, comprising approximately 12 000 lung cancer patients per year worldwide. Furthermore, considering RET mutations to be traditionally known thyroid cancer drivers, it is noteworthy that none of the subjects with KIF5B-RET-positive NSCLCs had a history of thyroid cancer or showed abnormal findings in their thyroid tissues but showed 2- to 30-fold higher levels of RET expression in noncancerous lung tissues. All subjects with LADC having the KIF5B-RET fusion were negative to the known cancer driver mutations, including EGFR, KRAS, ALK, and HER2, suggesting that KIF5B-RET is a new cancer driver mutation in LADCs. It was also shown that cells expressing oncogenic KIF5B-RET are sensitive to multikinase RET inhibitors, including sorafenib, sunitinib, and vandetanib, by decreasing the growth and signaling properties mediated by KIF5B-RET; however, an EGFR kinase inhibitor, gefitinib, showed no inhibitory activity against RET phosphorylation in Ba/F3 cells with the KIF5B-RET fusion protein.<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> Triggered by these findings based on preclinical activity, several related clinical trials for NSCLC patients with KIF5B-RET rearrangements are currently ongoing using previously known RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The anti-RET activity and the clinical development status of the known RET TKIs for both thyroid cancer and KIF5B-RET fusion-positive NSCLC are discussed below.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic representations of wild-type KIF5B, RET proteins, and KIF5B-RET fusions in LADC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Small-molecule RET inhibitors under clinical development for NSCLC with KIF5B-RET rearrangements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among 23 TKIs approved for cancer treatment by the U.S. FDA as of April 2014,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> about nine small-molecule tyrosine kinase inhibitors are known to have anti-RET activity.<a onclick="showRef(event, 'ref17 ref52'); return false;" href="javascript:void(0);" class="ref ref17 ref52">(17, 52)</a> The anti-RET activities and the other major targets for some selected small-molecule kinase inhibitors are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Among these, five TKIs are presently under clinical development for the treatment of NSCLC with KIF5B-RET fusion genes (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selected FDA-Approved Tyrosine Kinase Inhibitors with Anti-RET Activity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd (compd class)</th><th class="colsep0 rowsep0" align="center">anti-RET activity (IC<sub>50</sub>, nM)</th><th class="colsep0 rowsep0" align="center">other major targets</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vandetanib (4-anilinoquinazoline)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">(V)EGFR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cabozantinib (dicarboxamide)</td><td class="colsep0 rowsep0" align="left">5–10</td><td class="colsep0 rowsep0" align="left">VEGFR, MET, TIE2, AXL, FLT3, KIT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sorafenib (urea)</td><td class="colsep0 rowsep0" align="left">6–47</td><td class="colsep0 rowsep0" align="left">Raf1, B-Raf, VEGFR1-3, PDGFR, FLT3, KIT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib (2-indolinone)</td><td class="colsep0 rowsep0" align="left">220–1300</td><td class="colsep0 rowsep0" align="left">VEGFR1-2, PDGFRβ, FLT3, KIT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lenvatinib (urea)</td><td class="colsep0 rowsep0" align="left">1.5 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">VEGFR1-3, FGFR1-4, PDGFR, KIT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">motesanib (nicotinamide)</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">VEGFR1-3, PDGFR, KIT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ponatinib (benzamide)</td><td class="colsep0 rowsep0" align="left">25.8</td><td class="colsep0 rowsep0" align="left">BCR-ABL, SCR, FLT3, KIT, FGFR, VEGFR, PDFGR</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; TIE2, tyrosine kinase with immunoglobulin-like and EGF-like domains 2; FLT3, FMS-like tyrosine kinase 3; Raf, rapidly accelerated fibrosarcoma; PDGFR, platelet-derived growth factor receptor; MTC, medullary thyroid cancer; DTC, differentiated thyroid cancer; NSCLC, non-small-cell lung cancer; AML, acute myeloid leukemia.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Small-Molecule RET Inhibitors Approved for Clinical Study</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> </h3><div class="NLM_p last"><b>Lenvatinib</b> (E7080, Eisai) is a multikinase inhibitor showing inhibitory activity against VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Recently, the results from the phase III SELECT (<b>S</b>tudy of (E7080) <b>LE</b>nvatinib in differentiated <b>C</b>ancer of the <b>T</b>hyroid) trial for radioiodine-refractory differentiated thyroid cancer (RR-DTC) have been released showing significantly improved progression-free survival (PFS), although the overall survival (OS) data were somewhat troublesome.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Okamoto et al. showed that lenvatinib inhibited autophosphorylation of RET fusion genes, including KIF5B-RET, CCDC6-RET, and NcoA4-RET, with IC<sub>50</sub> values in the 10 nM range. Additionally, lenvatinib exhibited antitumor activity in vivo by suppressing tumor growth driven by RET fusion-transformed NIH3T3 cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> A phase II clinical trial of lenvatinib is currently ongoing for KIF5B-RET-positive LADCs and other confirmed RET translocations.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> </h3><div class="NLM_p last"><b>Vandetanib</b> (ZD6474, AstraZeneca) belongs to the quinazoline class of compounds and is a broad-spectrum kinase inhibitor. It inhibits VEGFR2-3, EGFR, and RET as the major targets.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Vandetanib suppressed RET autophosphorylation and downstream signaling in cells transformed by both MEN2- and PTC-associated RET mutants. As a result, vandetanib blocked growth of NIH-RET/PTC3, showing specific anti-RET activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In April 2011, vandetanib became the first drug approved by the FDA for the treatment of late-stage (metastatic) medullary thyroid cancer (MTC). This therapeutic activity is likely caused by inhibition of RET.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Currently, vandetanib is undergoing a phase II investigational clinical trial for advanced NSCLC with RET rearrangements sponsored by Seoul National University Hospital, Korea. Because vandetanib has diminished growth and signaling properties mediated by KIF5B-RET, as mentioned earlier, the purpose of this investigational study is to examine the efficacy and safety of this drug.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In a preliminary efficacy report by Gautschi et al., vandetanib showed a favorable response after 1 week of treatment in a patient with KIF5B-RET-positive NSCLC.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> </h3><div class="NLM_p last"><b>Sunitinib</b> (SU11284, Pfizer) is a multikinase inhibitor that belongs to the indolinone class of compounds.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In 2006, sunitinib was the first cancer drug to be approved by the U.S. FDA simultaneously for the treatment of imatinib-resistant gastrointestinal stromal tumors (GIST) and advanced renal cell carcinoma (RCC, kidney cancer), and it was further approved for the treatment of advanced pancreatic neuroendocrine tumors in 2011. Kim et al. reported that sunitinib is a potent inhibitor of the oncogenic RET/PTC tyrosine kinase by showing decreased autophosphorylation of RET/PTC with an IC<sub>50</sub> of 224 nM, and RET/PTC-mediated Y705 phosphorylation of STAT3 was also inhibited by sunitinib.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Because sunitinib works by blocking certain protein signals within the cell, it is proposed that sunitinib may be useful for targeted therapy of PTC. To investigate the efficacy of sunitinib, an investigational phase II clinical study is underway by the Dana-Farber Cancer Institute. The purpose is aimed at verifying sunitinib’s efficacy in certain types of adenocarcinoma tumors (1) that do not carry a mutation in a known cancer gene (EGFR, KRAS, or ALK) and occur in nonsmokers (less than 100 cigarettes in a lifetime) or (2) that have a mutation in the RET gene.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> </h3><div class="NLM_p last"><b>Cabozantinib</b> (XL184, Exelixis), a dicarboxamide-containing compound, inhibits a broad range of tyrosine kinases, including VEGFR, MET, and RET as the major target kinases. Originally developed as a dual inhibitor of VEGFR2 and MET for MTC, it was reported at the ASCO 2012 meeting that in the phase III EXAM (Efficacy of XM184 in Advanced Medullary Thyroid Cancer) trial, cabozantinib showed progression-free survival (PFS) of 11.2 months, 1 year progression-free survival of 47.3%, and an overall response rate of 28%, regardless of RET mutation status.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> On the basis of these results, the drug was approved by the FDA for the treatment of medullary thyroid cancer (MTC) in late 2012. Comparing cabozantinib with vandetanib and sunitinib, it is noteworthy that cabozantinib is the most potent against RET, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Preliminary clinical efficacy of cabozantinib in advanced, KIF5B-RET-positive NSCLC was reported by Drilon et al. Among three patients treated with cabozantinib in the phase II trial for patients with RET fusion-positive NSCLCs, confirmed partial responses were observed in two patients, and a third patient had prolonged stable disease for more than 8 months (31 weeks). All three patients remained progression-free on treatment.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Currently, it is undergoing a phase II clinical study for the treatment of non-small-cell lung cancer (NSCLC) with KIF5B-RET mutations, with the aim of determining the good and/or bad effects of cabozantinib.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> </h3><div class="NLM_p last"><b>Ponatinib</b> (AP24534, ARIAD), a member of a new class of compounds, is also a multitargeted, broad-spectrum tyrosine kinase inhibitor which has shown inhibitory activities against BCR-ABL, SCR, FLT3, RET, KIT, FGFR, VEGFR, PDFGR, and others. Ponatinib was approved in late 2012 for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Recently, De Falco et al. reported that ponatinib inhibited RET with an IC<sub>50</sub> of 25.8 nM and RET/V804 with an IC<sub>50</sub> of 33.9 nM and showed almost complete reduction of tumors in TT cell (MTC cells harboring the RET/C634W mutation) xenografts after 3 weeks of ponatinib treatment (30 mg/kg/d).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Additionally, unlike vandetanib, which is inactive against RET mutants carrying side chains bulkier than the isopropyl group of Val<sup>804</sup>, Mologni et al. showed that ponatinib exhibited potent inhibition against both RET and vandetanib-resistant V804M/L mutations in cellular assays.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In early 2013, an investigational phase II clinical trial of ponatinib for NSCLC was designed to examine only patients with a RET mutation to study the efficacy of the drug in inhibiting or shutting off growth signals. However, in late 2013, the FDA requested the suspension of sales of the drug because of safety concerns caused by a steady increase in the number of serious vascular occlusion events, such as blood clots and severe narrowing of blood vessels; consequently, the phase II study is currently on hold.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> </h3><div class="NLM_p last"><b>Sorafenib</b> (Bayer & Onyx), a urea-containing compound, is a multityrosine kinase inhibitor targeting RAF, MEK, ERK, VEGFR1-3, PDGFR, KIT, RET, CRAF, and BRAF.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Sorafenib was approved by the U.S. FDA for kidney cancer in 2005 and for liver cancer in 2007, and in late 2013, it was approved for radioiodine refractory differentiated thyroid cancer (RR-DTC). Plaza-Menacho et al. previously reported that sorafenib showed anti-RET activity by blocking enzymatic activity with an IC<sub>50</sub> of 5.9 nM in vitro and inhibited RET phosphorylation, downstream signaling, and cell proliferation in human tumor cells expressing both wild-type and different oncogenic RET variants at concentrations of 15–150 nM.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> </h3><div class="NLM_p"><b>Motesanib</b> (AMG706, Amgen), in the nicotinamide class of compounds, is another multikinase inhibitor that blocks VEGFR, PDGFR, Kit, and RET as the major targets. Motesanib is an investigational drug that is in several clinical studies. Coxon et al. has demonstrated that motesanib inhibited the activity of wild-type RET with an IC<sub>50</sub> of 66 nM in a cellular phosphorylation assay, and in vivo studies resulted in a substantial decrease in the growth of TT tumor cell xenografts.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Although nothing is known about both compounds’ activities against the KIF5B-RET fusion gene, if one considers the anti-RET activity of sorafenib and motesanib both in vitro and in vivo, it will be interesting if these results can translate into activity against KIF5B-RET driven NSCLC, as other anti-RET TKIs are employed in related clinical studies due to their anti-RET activities.</div><div class="NLM_p"><b>AUY922</b> (5-(2,4-dihydroxy-5-isopropylphenyl)-<i>N</i>-ethyl-4-[4-(morpholinomethyl)phenyl]isoxazole-3-carboxamide, NVP-AUY922, VER-52296, Vernalis/Novartis), a diaryl isoxazole compound and HSP90 inhibitor, is in a phase II clinical trial for a rather broad range of NSCLC patients, including stage IV EGFR T790M, EGFR exon 20, and other uncommon, HER2, or BRAF-mutated and ALK, ROS1, or RET-rearranged NSCLCs. In a related study, Gild et al. has reported that AUY922 decreased cell viability in <i>RET</i> mutant medullary thyroid cancer cell lines and impaired signaling through the MAPK and mTOR pathways.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Because AUY922 is intended to treat NSCLC patients with RET translocations resulting in KIF5B-RET fusions, as well as patients with other NSCLC drivers, it is of interest whether indirect regulation of AUY922 would result in a decrease of KIF5B-RET-associated tumor growth.</div><div class="NLM_p">Although these RET-inhibiting TKIs will provide valuable new therapeutic tools for use in RET-associated tumors, including those of the lung, the thyroid, and others, unwanted adverse side effects are of high concern because these are all broad-spectrum kinase inhibitors. It has been reported that an objective response rate from vandetanib and cabozantinib in treating thyroid cancer is presumably increased by the inhibition of VEGFR or EGFR, in addition to RET, and that adverse side effects are associated with VEGFR or EGFR inhibition.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> It is also known that the high TKI response rates in RET-associated tumors have been partial responses, leading to stable disease or progression-free survival,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> which suggests that longer term exposure to the currently available TKIs in patients with RET-associated tumors is necessary and will most likely lead to acquired drug resistance. Additionally, most of these TKIs show multikinase inhibitory activity and are known to work in an ATP-competitive manner. ATP-competitive inhibitors are highly potent but can inhibit other receptor tyrosine kinases because of their structural similarities; therefore, they can be less specific and may cause unintended adverse effects. Hence, development of more potent and RET-specific inhibitors are in high demand to limit undesired adverse effects. As an example of new drug discovery strategies, Dar et al. used a RET-driven <i>drosophila</i> model of MEN2 and kinome-wide drug profiling as a novel phenotypic screening strategy to identify potential RET inhibitors with maximal therapeutic indices.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> It is expected that a kinase inhibitor that can target a driver mutation specifically may lead to a superior clinical benefit compared to broad-spectrum kinase inhibitors.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. TKIs in Clinical Trials for KIF5B-RET-Associated NSCLC<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd [manufacturer]</th><th class="colsep0 rowsep0" align="center">selected clinical studies (sponsor, clinical trial identifier code, estimated primary completion date)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lenvatinib [Eisai]</td><td class="colsep0 rowsep0" align="left">Ph II (2013–, recruiting): For patients with KIF5B-RET-positive LADCs and other confirmed RET translocations. (Eisai, NCT01877083, Sep 2014)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vandetanib [AstraZeneca]</td><td class="colsep0 rowsep0" align="left">Ph II (2013–, recruiting): For patients with advanced NSCLC harboring a RET gene rearrangement. (Seoul National University Hospital, collaborator: AstraZeneca, NCT01823068, Sep 2015)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib [Pfizer]</td><td class="colsep0 rowsep0" align="left">Ph II (2013–, recruiting): For never-smoker LADCs w/o known cancer genes other than RET mutations. (Dana-Farber Cancer Institute, NCT01829217, June 2015)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ponatinib [ARIAD]</td><td class="colsep0 rowsep0" align="left">Ph II (2013–, suspended): For advanced NSCLC w/RET translocation. Suspended because of a steady increase in the number of serious vascular occlusion events, such as blood clots and severe narrowing of blood vessels (Massachusetts General Hospital, NCT01813734, suspended)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cabozantinib [Exelixis]</td><td class="colsep0 rowsep0" align="left">Ph II (2013–, recruiting): For patients whose tumors have a gene called KIF5B/RET. Cabozantinib in patients with RET fusion-positive advanced non-small-cell lung cancer. (Memorial Sloan-Kettering Cancer Center, collaborator: Exelixis, NCT01639508, July 2015)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NVP-AUY922 (AUY922) [Novartis]</td><td class="colsep0 rowsep0" align="left">Ph II (2013–, recruiting in plan): For patients with stage IV EGFR T790M, EGFR exon 20, and other uncommon, HER2, or BRAF mutated and ALK-, ROS1-, or RET-rearranged NSCLCs. (National Taiwan University Hospital, NCT01922583, Aug 2016)</td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">X-ray Crystal Structure</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A more effective and even a target-specific inhibitor may be derived by deciphering the structure of RET kinase and its complex with known RET inhibitors and understanding the binding mode of those inhibitors. According to Kohno et al., vandetanib suppressed both the phosphorylation of Tyr<sup>905</sup>, which is located in the activation loop of the RET kinase site of KIF5B-RET, and anchorage-independent growth of NIH3T3 cells expressing KIF5B-RET, suggesting that the RET fusions are potential targets for existing small-molecule TKIs.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Lipson et al. also independently demonstrated that Ba/F3 cells expressing KIF5B-RET were sensitive to anti-RET-active small-molecule TKIs, including vandetanib, sorafenib, and sunitinib, but not to an EGFR inhibitor, gefitinib. Additionally, the phosphorylation of Ba/F3 cells was inhibited by sunitinib.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Both of these findings clearly suggest that the KIF5B-RET fusions are potential targets for existing anti-RET TKIs. As mentioned previously, two small-molecule broad-spectrum TKIs, vandetanib and cabozantinib, are approved by the U.S. FDA for MTC, and despite the presence of RET fusions in papillary thyroid cancers (PTC), no RET kinase inhibitors have been clinically evaluated thoroughly for RET-fusion positive thyroid cancers. Furthermore, there are no RET-specific inhibitors known to date. Because all current RET targeted TKIs are multikinase inhibitors, the increased response rate from inhibition of other receptor tyrosine kinases (RKTs), such as VEGFRs, is also presumed.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35-37)</a> As mentioned above, adverse effects that are linked to VEGFR or EGFR inhibition can be significant, and how such “targeted” agents actually function remains unclear.<a onclick="showRef(event, 'ref36 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref38 ref39">(36, 38, 39)</a> Therefore, more potent and RET-specific inhibitors are clearly needed, and they would provide an important new stepping stone in curing RET-related diseases. In this regard, understanding the binding mode of anti-RET TKIs targeting the RET kinase domain could provide valuable information in deriving a highly selective KIF5B-RET inhibitor. Although the crystal structure of KIF5B-RET is unknown, it is known that the KIF5B-RET fusion gene has a kinase domain identical to RET kinase. Furthermore, the crystal structure of the phosphorylated RET kinase domain in complex with chemical inhibitors, such as vandetanib and PP1, in the ATP pocket has been elucidated by Knowles et al., as shown in Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Both inhibitors block the autophosphorylation and substrate phosphorylation of RET in an ATP-competitive fashion and prevent its oncogenic activity. From the X-ray crystallography structures, PP1 formed two hydrogen bonds with the linker (hinge) region, one each with Ala<sup>807</sup> and Glu<sup>805</sup>, and vandetanib formed only one hydrogen bond with Ala<sup>807</sup>. The tolyl group of PP1 and the bromofluorophenyl group of vandetanib each occupy a pocket located in the back of the ATP binding site (hydrophobic back pocket).<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> The hydrophobic back pocket has Val<sup>804</sup> in the gatekeeper position. The gatekeeper residue Val<sup>804</sup> controls access to the pocket and kinase sensitivity to the corresponding small-molecule TKIs.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> For example, vandetanib is able to selectively inhibit EGFR, VEGFR2, and RET but not IRK,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> in which the larger methionine side chain occupies the gatekeeper position. Additionally, although Val<sup>804</sup> of RET cannot form hydrogen bonds with the inhibitors, the size of the isopropyl group of Val<sup>804</sup> controls access to the pocket, which explains why Val<sup>804</sup> mutants, such as MTC and MEN2 with the bulkier leucine or methionine groups, respectively, are not inhibited by vandetanib.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> Upon the basis of these findings, Grøtli et al. have utilized an extended hydrophobic arm, such as a phenylacetylene, on the pyrazolopyrimidine scaffold of PP1 to fit into the hydrophobic back pocket deeper than the tolyl group of PP1 and the bromofluorophenyl group of vandetanib, resulting in improved in vitro inhibitory activity against RET (IC<sub>50</sub> = 8 nM) and selectivity against other kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ligand binding sites. Electron density maps around ZD6474 (A) and PP1 (B) show REFMAC-calculated electron density maps with 2<i>mF</i><sub>o</sub> −<i>DF</i><sub>c</sub> contoured at 1σ in green and <i>mF</i><sub>o</sub> – <i>DF</i><sub>c</sub> contoured at 3σ in blue and (in part A) contoured at 8σ in red. Parts C and D are Ligplot schematic diagrams of vandetanib and PP1 contacts with RET. Water molecules (W) are shown in cyan. Parts E–G show molecular surfaces of the ligand binding pockets in RET-KD-P, with the solvent side of the surface in white and the inside of the surface in blue-green. Ligands are shown in stick form, with carbon atoms in magenta for vandetanib (<i>E</i>), green for AMP (F), and brown for PP1 (G). The Val<sup>804</sup> side chain is highlighted in yellow. The pocket with access that is controlled by Val<sup>804</sup> is in the center of each diagram; a second apparent pocket (∗) in parts E and G is the result of the Phe<sup>735</sup> side chain being disordered in these two complexes. This research was originally published in  <cite>J. Biol. Chem.</cite> <span class="NLM_year">2006</span>, <em>281</em>, 33577–33587.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> ©American Society for Biochemistry and Molecular Biology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mapping of disease-linked mutations in the RET kinase structure. Activating mutation sites in RET-KD identified in MTC, MEN2A, and MEN2B. Carbon atoms of the side chains are colored magenta for M918T, the predominant MEN2B mutant; pink for E768D/A919P; white for V804M/Y806C, two paired mutations where there is synergy; and cyan for L790F, Y791F, S891A, and R844L. The backbone schematic of RET-KD is shown in green, with the link to the N-terminal helix and the kinase insert domain indicated by dashed lines. The side chains of the wild-type RET-KD are shown, and the bound nucleotide is shown in stick form. This research was originally published in  <cite>J. Biol. Chem.</cite> <span class="NLM_year">2006</span>, <em>281</em>, 33577–33587.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> ©American Society for Biochemistry and Molecular Biology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding modes of small-molecule RET kinase inhibitors. Kinase inhibitor–protein interactions are depicted in the chemical structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since its first discovery as a proto-oncogene in human thyroid cancer in 1990,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> RET has become an important target for diverse tumor types, and numerous tyrosine kinase inhibitors have been developed that target the RET receptor, in addition to targeting other receptors, such as VEGFR. These RET-inhibiting TKIs include cabozantinib, vandetanib, sunitinib, and axitinib. However, for each agent, the degree of RET inhibition relative to inhibition of other receptors varies greatly, and similarly, the potency against RET differs between agents. Furthermore, potency may vary according to the particular type of RET mutation.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p last">After the discovery of the EML4-ALK fusion gene in 2007, the ALK TKI crizotinib was swiftly developed, and in clinical trials crizotinib showed a dramatic therapeutic effect against NSCLCs harboring ALK fusions.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48-50)</a> On the basis of these results, crizotinib was approved by the U.S. FDA in 2011, 4 years after the discovery of the EML4-ALK fusion gene in 2007. In the less than 2 years that have elapsed since the discovery of KIF5B-RET in late 2012, several phase II clinical trials of RET TKIs for NSCLCs with KIF5B-RET fusions are currently ongoing, and all are open-label, single-arm trials with response rate as the primary end point.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Among six phase II clinical studies, five studies are sponsored by nonprofit organizations as an investigational clinical trial which directly indicates the urgency and the high demand of a new targeted therapy for KIF5B-RET positive NSCLC. To date, one positive report about the clinical efficacy of cabozantinib has been published as a preliminary result.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Since most of these RET TKIs are broad spectrum inhibitors, adverse side effects associated with VEGFR or EGFR inhibition are still of concern. Because the potency and the selectivity against RET differ between agents, the degree of RET inhibition in KIF5B/RET positive NSCLCs will vary. Acquired drug resistance by long-term exposure to these RET TKIs in patients can be a potential problem as well. The clinical results from current phase II studies will provide invaluable answers to these questions also with important biological information associated with KIF5B-RET positive NSCLC. Because these phase II clinical trials are expected to be completed by at least 2015, it is anticipated that a new RET TKI will follow crizotinib’s path and become available as an additional personalized targeted therapy for NSCLC patients in a couple of years. Additionally, other potent small-molecule anti-RET TKIs, such as sorafenib and motesanib, are known to be effective for thyroid cancer. Thus, an additional therapy for KIF5B-RET-positive adenocarcinomas is expected to be just around the corner.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm501464c" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minsoo Song</span> - <span class="hlFld-Affiliation affiliation">New Drug
Development Center (NDDC), Daegu-Gyeongbuk
Medical Innovation Foundation (DGMIF), 80 Cheombok-ro, Dong-gu, Daegu 701-310, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#026f716d6c654266656f6b642c70672c6970"><span class="__cf_email__" data-cfemail="0f627c6061684f6b68626669217d6a21647d">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74111" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74111" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Minsoo Song</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=BIO-d2782e777-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Minsoo Song</b> acquired his Ph.D. degree in Synthetic Organic Chemistry under the direction of Prof. John Montgomery at Wayne State University, MI, in 2004, and pursued postdoctoral training under the mentoring of Prof. Franklin A. Davis at Temple University, PA. He began his medicinal chemistry career at Cumbre in Dallas, TX, working on infectious disease projects. Then he worked at PsychoGenics in Tarrytown, NY, to pusue CNS disorder projects including NAAG peptidase inhibitor for TBI. In Korea, he pursued several kinase-related projects for arthritis and cancer at Oscotec, Inc. He is now a principal research scientist at NDDC at DGMIF, Daegu, Korea. His research interests lie in medicinal chemistry and drug discovery in the area of CNS disorders, oncology, and infectious diseases.</p></figure></div><div class="ack" id="ACK-d2782e782-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The author is grateful to DGMIF colleagues Drs. Suk Kyoon Yoon, Seongheon Kim, Kyung-Hee Kim, Soosung Kang, and Hwan Geun Choi for their critiques; to Dr. Jong Sung (John) Koh at Genosco (Oscotec) for his inspirational leadership during the author’s stay at Oscotec; and to the editorial office and the reviewers for their careful review and critical suggestions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> Abbreviations Used</h2><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson murine leukemia viral oncogene homolog</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B (PKB)</p></td></tr><tr><td class="NLM_term">ANLK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">breakpoint cluster region protein</p></td></tr><tr><td class="NLM_term">CLD</td><td class="NLM_def"><p class="first last">cadherin-like domain</p></td></tr><tr><td class="NLM_term">CRD</td><td class="NLM_def"><p class="first last">cystein-rich domain</p></td></tr><tr><td class="NLM_term">DTC</td><td class="NLM_def"><p class="first last">differentiated thyroid cancer</p></td></tr><tr><td class="NLM_term">EML</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">FMTC</td><td class="NLM_def"><p class="first last">familial medullary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">GDNF</td><td class="NLM_def"><p class="first last">glial-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">IRK</td><td class="NLM_def"><p class="first last">insulin receptor kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">KIF5B</td><td class="NLM_def"><p class="first last">kinesin family 5B gene</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">GTPase KRas, also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog</p></td></tr><tr><td class="NLM_term">LADC</td><td class="NLM_def"><p class="first last">lung adenocarcinoma</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MEN2A and MEN2B</td><td class="NLM_def"><p class="first last">multiple endocrine neoplasia 2 syndromes</p></td></tr><tr><td class="NLM_term">MTC</td><td class="NLM_def"><p class="first last">medullary thyroid cancer</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survivla</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression free survival</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">Raf</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">Rearranged during Transcription</p></td></tr><tr><td class="NLM_term">RR-DTC</td><td class="NLM_def"><p class="first last">radioiodine-refractory differentiated thyroid cancer</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SCLC</td><td class="NLM_def"><p class="first last">small cell lung cancer</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TIE2</td><td class="NLM_def"><p class="first last">tyrosine kinase with immunoglobulin-like and EGF-like domains 2</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>World Cancer Research Fund International. <a href="http://www.wcrf.org/index.php" class="extLink">http://www.wcrf.org/index.php</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Cancer+Research+Fund+International.+http%3A%2F%2Fwww.wcrf.org%2Findex.php+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span>National Cancer Institute. Surveillance, Epidemiology, and End Results Program. <a href="http://seer.cancer.gov" class="extLink">http://seer.cancer.gov</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Cancer+Institute.+Surveillance%2C+Epidemiology%2C+and+End+Results+Program.+http%3A%2F%2Fseer.cancer.gov+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>American Cancer Society. Cancer Facts and Figures 2014. <a href="http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/" class="extLink">http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=American+Cancer+Society.+Cancer+Facts+and+Figures+2014.+http%3A%2F%2Fwww.cancer.org%2Fresearch%2Fcancerfactsstatistics%2Fcancerfactsfigures2014%2F+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Minuti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incecco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span> </span><span class="NLM_article-title">Targeted therapy for NSCLC with driver mutations</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1517%2F14712598.2013.827657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23930754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVektrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1401-1412&author=G.+Minutiauthor=A.+D%E2%80%99Inceccoauthor=F.+Cappuzzo&title=Targeted+therapy+for+NSCLC+with+driver+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for NSCLC with driver mutations</span></div><div class="casAuthors">Minuti, Gabriele; D'Incecco, Armida; Cappuzzo, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1401-1412</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Activating mutations of the epidermal growth factor receptor (EGFR) gene and rearrangement of anaplastic lymphoma kinase (ALK) gene best illustrate the therapeutic relevance of mol. characterization in non-small cell lung cancer (NSCLC) patients.  Several genetic aberrations with a potential prognostic or predictive role have been identified, mainly in adenocarcinoma subtype, including ROS1, RET, MET, HER2, BRAF and KRAS.  More recently oncogenic drivers, such as DDR2, FGFR1 and PI3KCA, have been characterized in squamous cell lung carcinoma (SCC) and target agents are currently under evaluation.  The aim of this review is to summarize the growing scenario of new targetable oncogenes in NSCLC.  Areas covered: For this review article all published data on NSCLC genomic alterations, including the techniques employed for oncogenic drivers identification, the prevalence of each one in lung cancer subtypes, the preclin. data corroborating their role in tumorigenesis and the potential biol. tailored agents tested and under evaluation were collected and analyzed using PubMed.  Expert opinion: Oncogenic products represent reliable targets for drug therapy and the expanding knowledge of mol. pathways involved in lung tumorigenesis is resulting in a dramatic change of treatment strategies leading to an improvement in disease and symptom control, extending life duration and improving quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodEsO_1XneLVg90H21EOLACvtfcHk0lh2gtn5tBlcoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVektrbM&md5=d5ef58a3a80f9bb5c49b4c7d8567a949</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14712598.2013.827657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2013.827657%26sid%3Dliteratum%253Aachs%26aulast%3DMinuti%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Incecco%26aufirst%3DA.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DTargeted%2520therapy%2520for%2520NSCLC%2520with%2520driver%2520mutations%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D1401%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Forde, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, D. S.</span><span> </span><span class="NLM_article-title">Targeted therapy for non-small-cell lung cancer: past, present and future</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">758</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1586%2Fera.13.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23773106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFKiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=745-758&author=P.+M.+Fordeauthor=D.+S.+Ettinger&title=Targeted+therapy+for+non-small-cell+lung+cancer%3A+past%2C+present+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for non-small-cell lung cancer: past, present and future</span></div><div class="casAuthors">Forde, Patrick M.; Ettinger, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-758</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histol. subtype as an important factor in guiding treatment and the development of targeted agents for mol. subgroups harboring crit. mutations that spur on cancer growth.  In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK.  This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz1_lFCYvFNbVg90H21EOLACvtfcHk0lgCLFPiIj3JCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFKiur8%253D&md5=fdd2c66ec4e6d506a28d0f57c6a4d012</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1586%2Fera.13.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.13.47%26sid%3Dliteratum%253Aachs%26aulast%3DForde%26aufirst%3DP.%2BM.%26aulast%3DEttinger%26aufirst%3DD.%2BS.%26atitle%3DTargeted%2520therapy%2520for%2520non-small-cell%2520lung%2520cancer%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D745%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><div class="note"><p class="first last">A review on irreversible kinase inhibitors.</p></div><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lgCLFPiIj3JCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span>U.S. Food and Drug Administration. News & Events (released Apr 29,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span><a href="http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm" class="extLink">http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+and+Drug+Administration.+News+%26+Events+%28released+Apr+29%2C+2014%29+http%3A%2F%2Fwww.fda.gov%2Fnewsevents%2Fnewsroom%2Fpressannouncements%2Fucm395299.htm+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, K. E.</span><span> </span><span class="NLM_article-title">Chipping away at the lung cancer genome</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22395697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1yhtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=349-351&author=W.+Paoauthor=K.+E.+Hutchinson&title=Chipping+away+at+the+lung+cancer+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Chipping away at the lung cancer genome</span></div><div class="casAuthors">Pao, William; Hutchinson, Katherine E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-351</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are now std. treatment for patients with lung cancer whose tumors harbor specific mutant kinases.  Four recent studies, including 3 in this issue (pages 375-384), have identified new fusion proteins involving another receptor tyrosine kinase that may potentially be responsive to existing targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMVnaQExHaYrVg90H21EOLACvtfcHk0lhC0lAIkpVeLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1yhtrs%253D&md5=8ab9f744a70dc422ebad03650ce22367</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.2697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2697%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DHutchinson%26aufirst%3DK.%2BE.%26atitle%3DChipping%2520away%2520at%2520the%2520lung%2520cancer%2520genome%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D349%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kohno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totoki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiramoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nammo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada1, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwakawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogiwara1, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oike, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaug, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiku, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekine, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T.</span><span> </span><span class="NLM_article-title">KIF5B-RET fusion in lung adenocarcinoma</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22327624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=375&author=T.+Kohnoauthor=H.+Ichikawaauthor=Y.+Totokiauthor=K.+Yasudaauthor=M.+Hiramotoauthor=T.+Nammoauthor=H.+Sakamotoauthor=K.+Tsutaauthor=K.+Furutaauthor=Y.+Shimada1author=R.+Iwakawaauthor=H.+Ogiwara1author=T.+Oikeauthor=M.+Enariauthor=A.+J.+Schetterauthor=H.+Okayamaauthor=A.+Haugenauthor=V.+Skaugauthor=S.+Chikuauthor=I.+Yamanakaauthor=Y.+Araiauthor=S.-i.+Watanabeauthor=I.+Sekineauthor=S.+Ogawaauthor=C.+C.+Harrisauthor=H.+Tsudaauthor=T.+Yoshidaauthor=J.+Yokotaauthor=T.+Shibata&title=KIF5B-RET+fusion+in+lung+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">KIF5B-RET fusions in lung adenocarcinoma</span></div><div class="casAuthors">Kohno, Takashi; Ichikawa, Hitoshi; Totoki, Yasushi; Yasuda, Kazuki; Hiramoto, Masaki; Nammo, Takao; Sakamoto, Hiromi; Tsuta, Koji; Furuta, Koh; Shimada, Yoko; Iwakawa, Reika; Ogiwara, Hideaki; Oike, Takahiro; Enari, Masato; Schetter, Aaron J.; Okayama, Hirokazu; Haugen, Aage; Skaug, Vidar; Chiku, Suenori; Yamanaka, Itaru; Arai, Yasuhito; Watanabe, Shun-ichi; Sekine, Ikuo; Ogawa, Seishi; Harris, Curtis C.; Tsuda, Hitoshi; Yoshida, Teruhiko; Yokota, Jun; Shibata, Tatsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-377</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing.  The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQqNYV3xGfbVg90H21EOLACvtfcHk0lhC0lAIkpVeLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D&md5=301f964ad413e020aba11122dff13054</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnm.2644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2644%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DTotoki%26aufirst%3DY.%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DHiramoto%26aufirst%3DM.%26aulast%3DNammo%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DFuruta%26aufirst%3DK.%26aulast%3DShimada1%26aufirst%3DY.%26aulast%3DIwakawa%26aufirst%3DR.%26aulast%3DOgiwara1%26aufirst%3DH.%26aulast%3DOike%26aufirst%3DT.%26aulast%3DEnari%26aufirst%3DM.%26aulast%3DSchetter%26aufirst%3DA.%2BJ.%26aulast%3DOkayama%26aufirst%3DH.%26aulast%3DHaugen%26aufirst%3DA.%26aulast%3DSkaug%26aufirst%3DV.%26aulast%3DChiku%26aufirst%3DS.%26aulast%3DYamanaka%26aufirst%3DI.%26aulast%3DArai%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DS.-i.%26aulast%3DSekine%26aufirst%3DI.%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DYokota%26aufirst%3DJ.%26aulast%3DShibata%26aufirst%3DT.%26atitle%3DKIF5B-RET%2520fusion%2520in%2520lung%2520adenocarcinoma%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamanaka, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninomiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okumura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span> </span><span class="NLM_article-title">RET, ROS1 and ALK fusion in lung cancer</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22327623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=378-381&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=R.+Suzukiauthor=S.+Sakataauthor=S.+Hatanoauthor=R.+Asakaauthor=W.+Hamanakaauthor=H.+Ninomiyaauthor=H.+Ueharaauthor=Y.+L.+Choiauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=H.+Manoauthor=Y.+Ishikawa&title=RET%2C+ROS1+and+ALK+fusion+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RET, ROS1 and ALK fusions in lung cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Suzuki, Ritsuro; Sakata, Seiji; Hatano, Satoko; Asaka, Reimi; Hamanaka, Wakako; Ninomiya, Hironori; Uehara, Hirofumi; Lim Choi, Young; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Mano, Hiroyuki; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">378-381</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Through an integrated mol.- and histopathol.-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-pos. and 13 ROS1-fusion-pos. adenocarcinomas, including for unidentified fusion partners for ROS1.  In addn., we discovered previously unidentified kinase fusions that may be promising for mol.-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain contg. 6 (CCDC6)-RET, in 14 adenocarcinomas.  A multivariate anal. of 1,116 adenocarcinomas contg. these 71 kinase-fusion-pos. adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathol. stage and neg. kinase-fusion status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJr0BIAnHWLVg90H21EOLACvtfcHk0liGIsXYm3z4_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D&md5=986c7eba0992b29950756e129a395d60</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm.2658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2658%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSakata%26aufirst%3DS.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DHamanaka%26aufirst%3DW.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DRET%252C%2520ROS1%2520and%2520ALK%2520fusion%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D378%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelensky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarosz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donahue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frampton, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juhn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell1, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwirko, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peretz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nechushtan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soussan-Gutman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span> </span><span class="NLM_article-title">Identification of new <i>ALK</i> and <i>RET</i> gene fusions from colorectal and lung cancer biopsies</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">382</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22327622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=382-384&author=D.+Lipsonauthor=M.+Capellettiauthor=R.+Yelenskyauthor=G.+Ottoauthor=A.+Parkerauthor=M.+Jaroszauthor=J.+A.+Curranauthor=S.+Balasubramanianauthor=T.+Bloomauthor=K.+W.+Brennanauthor=A.+Donahueauthor=S.+R.+Downingauthor=G.+M.+Framptonauthor=L.+Garciaauthor=F.+Juhnauthor=K.+C.+Mitchell1author=E.+Whiteauthor=J.+Whiteauthor=Z.+Zwirkoauthor=T.+Peretzauthor=H.+Nechushtanauthor=L.+Soussan-Gutmanauthor=J.+Kimauthor=H.+Sasakiauthor=H.+R.+Kimauthor=S.-i.+Parkauthor=D.+Ercanauthor=C.+E.+Sheehanauthor=J.+S.+Rossauthor=M.+T.+Croninauthor=P.+A.+J%C3%A4nneauthor=P.+J.+Stephens&title=Identification+of+new+ALK+and+RET+gene+fusions+from+colorectal+and+lung+cancer+biopsies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies</span></div><div class="casAuthors">Lipson, Doron; Capelletti, Marzia; Yelensky, Roman; Otto, Geoff; Parker, Alex; Jarosz, Mirna; Curran, John A.; Balasubramanian, Sohail; Bloom, Troy; Brennan, Kristina W.; Donahue, Amy; Downing, Sean R.; Frampton, Garrett M.; Garcia, Lazaro; Juhn, Frank; Mitchell, Kathy C.; White, Emily; White, Jared; Zwirko, Zac; Peretz, Tamar; Nechushtan, Hovav; Soussan-Gutman, Lior; Kim, Jhingook; Sasaki, Hidefumi; Kim, Hyeong Ryul; Park, Seung-il; Ercan, Dalia; Sheehan, Christine E.; Ross, Jeffrey S.; Cronin, Maureen T.; Jaenne, Pasi A.; Stephens, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-384</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clin. relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma.  Further screening of 561 lung adenocarcinomas identified 11 addnl. tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%).  Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9dSer699HbVg90H21EOLACvtfcHk0liGIsXYm3z4_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D&md5=9ab47602d1e1ed547cb852a34d29e5bb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2673%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DCurran%26aufirst%3DJ.%2BA.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DBloom%26aufirst%3DT.%26aulast%3DBrennan%26aufirst%3DK.%2BW.%26aulast%3DDonahue%26aufirst%3DA.%26aulast%3DDowning%26aufirst%3DS.%2BR.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DJuhn%26aufirst%3DF.%26aulast%3DMitchell1%26aufirst%3DK.%2BC.%26aulast%3DWhite%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DZwirko%26aufirst%3DZ.%26aulast%3DPeretz%26aufirst%3DT.%26aulast%3DNechushtan%26aufirst%3DH.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPark%26aufirst%3DS.-i.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DSheehan%26aufirst%3DC.%2BE.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26atitle%3DIdentification%2520of%2520new%2520ALK%2520and%2520RET%2520gene%2520fusions%2520from%2520colorectal%2520and%2520lung%2520cancer%2520biopsies%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D382%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Ju, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleazard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.-S.</span><span> </span><span class="NLM_article-title">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</span> <span class="citation_source-journal">Genome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1101%2Fgr.133645.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22194472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2lsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=436-445&author=Y.+S.+Juauthor=W.-C.+Leeauthor=J.-Y.+Shinauthor=S.+Leeauthor=T.+Bleazardauthor=J.-K.+Wonauthor=Y.+T.+Kimauthor=J.-I.+Kimauthor=J.-H.+Kangauthor=J.-S.+Seo&title=A+transforming+KIF5B+and+RET+gene+fusion+in+lung+adenocarcinoma+revealed+from+whole-genome+and+transcriptome+sequencing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</span></div><div class="casAuthors">Ju, Young Seok; Lee, Won-Chul; Shin, Jong-Yeon; Lee, Seungbok; Bleazard, Thomas; Won, Jae-Kyung; Kim, Young Tae; Kim, Jong-Il; Kang, Jin-Hyoung; Seo, Jeong-Sun</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">436-445</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The identification of the mol. events that drive cancer transformation is essential to the development of targeted agents that improve the clin. outcome of lung cancer.  Many studies have reported genomic driver mutations in non-small-cell lung cancers (NSCLCs) over the past decade; however, the mol. pathogenesis of >40% of NSCLCs is still unknown.  To identify new mol. targets in NSCLCs, we performed the combined anal. of massively parallel whole-genome and transcriptome sequencing for cancer and paired normal tissue of a 33-yr-old lung adenocarcinoma patient, who is a never-smoker and has no familial cancer history.  The cancer showed no known driver mutation in EGFR or KRAS and no EML4-ALK fusion.  Here we report a novel fusion gene between KIF5B and the RET proto-oncogene caused by a pericentric inversion of 10p11.22-q11.21.  This fusion gene overexpresses chimeric RET receptor tyrosine kinase, which could spontaneously induce cellular transformation.  We identified the KIF5B-RET fusion in two more cases out of 20 primary lung adenocarcinomas in the replication study.  Our data demonstrate that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggest the chimeric oncogene as a promising mol. target for the personalized diagnosis and treatment of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBEXolltRgLVg90H21EOLACvtfcHk0lhlDNIZjrfRBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2lsLk%253D&md5=a95455b1a7d548e5116be4f5107fd9f4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1101%2Fgr.133645.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.133645.111%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DY.%2BS.%26aulast%3DLee%26aufirst%3DW.-C.%26aulast%3DShin%26aufirst%3DJ.-Y.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBleazard%26aufirst%3DT.%26aulast%3DWon%26aufirst%3DJ.-K.%26aulast%3DKim%26aufirst%3DY.%2BT.%26aulast%3DKim%26aufirst%3DJ.-I.%26aulast%3DKang%26aufirst%3DJ.-H.%26aulast%3DSeo%26aufirst%3DJ.-S.%26atitle%3DA%2520transforming%2520KIF5B%2520and%2520RET%2520gene%2520fusion%2520in%2520lung%2520adenocarcinoma%2520revealed%2520from%2520whole-genome%2520and%2520transcriptome%2520sequencing%26jtitle%3DGenome%2520Res.%26date%3D2012%26volume%3D22%26spage%3D436%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span> </span><span class="NLM_article-title">RET revisited: expanding the oncogenic portfolio</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnrc3680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=24561444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=173-186&author=L.+M.+Mulligan&title=RET+revisited%3A+expanding+the+oncogenic+portfolio"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">RET revisited: expanding the oncogenic portfolio</span></div><div class="casAuthors">Mulligan, Lois M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-186</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RET receptor tyrosine kinase is crucial for normal development but also contributes to pathologies that reflect both the loss and the gain of RET function.  Activation of RET occurs via oncogenic mutations in familial and sporadic cancers - most notably, those of the thyroid and the lung.  RET has also recently been implicated in the progression of breast and pancreatic tumors, among others, which makes it an attractive target for small-mol. kinase inhibitors as therapeutics.  However, the complex roles of RET in homeostasis and survival of neural lineages and in tumor-assocd. inflammation might also suggest potential long-term pitfalls of broadly targeting RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohwDQSALnEwbVg90H21EOLACvtfcHk0lhlDNIZjrfRBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D&md5=665dae74c8f7a1df0e413ca15ca86440</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc3680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3680%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DRET%2520revisited%253A%2520expanding%2520the%2520oncogenic%2520portfolio%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D173%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span> </span><span class="NLM_article-title">Minireview: RET: Normal and abnormal functions</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">5448</span><span class="NLM_x">–</span> <span class="NLM_lpage">5451</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2004&pages=5448-5451&author=M.+Santoroauthor=R.+M.+Melilloauthor=F.+Carlomagnoauthor=G.+Vecchioauthor=A.+Fusco&title=Minireview%3A+RET%3A+Normal+and+abnormal+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DMelillo%26aufirst%3DR.%2BM.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26atitle%3DMinireview%253A%2520RET%253A%2520Normal%2520and%2520abnormal%2520functions%26jtitle%3DEndocrinology%26date%3D2004%26volume%3D145%26spage%3D5448%26epage%3D5451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span>Hematology/Oncology (Cancer) Approvals & Safety Notifications. <a href="http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm" class="extLink">http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hematology%2FOncology+%28Cancer%29+Approvals+%26+Safety+Notifications.+http%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm279174.htm+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span>Targeted Cancer Therapies. <a href="http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted" class="extLink">http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Targeted+Cancer+Therapies.+http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Ffactsheet%2FTherapy%2Ftargeted+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Development of RET kinase inhibitors for targeted cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.2174%2F092986711794088308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=21110809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVWrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=162-175&author=L.+Mologni&title=Development+of+RET+kinase+inhibitors+for+targeted+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of RET kinase inhibitors for targeted cancer therapy</span></div><div class="casAuthors">Mologni, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-175</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  RET (Rearranged during Transfection) is a transmembrane tyrosine kinase expressed in central and peripheral nervous system and neural crest-derived cells and acts as a co-receptor of GDNF family neurotrophic factor in complex with GRFα family proteins.  RET protein comprises an extracellular portion with four cadherine-like domains and a cysteine-rich region important for intermol. interactions; a hydrophobic transmembrane domain; an intracellular part comprising the juxtamembrane domain with regulatory function and the catalytic domain that phosphorylates the tyrosine residues of substrates.  RET is involved in the development of enteric nervous system and renal organogenesis during embryonic life.  Mutations of RET are assocd. to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer.  Activating point mutations in the cystein-rich or the kinase domain of RET cause multiple endocrine neoplasia type 2 (MEN2), a group of familial cancer syndromes characterized by medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia and ganglioneuromatosis of the gastroenteric mucosa.  Rearranged forms of RET (termed RET/PTC) are detected in the majority of papillary thyroid carcinomas (PTC).  At present, the therapeutic treatment available for these pathologies is the total or partial surgical removal of thyroid, assocd. with radio-iodine therapy or chemotherapy: despite widespread use of multimodality treatment, survival rates have not improved much in the past few decades, which suggests that new treatment options should be explored.  Several small-mol. inhibitors of RET kinase activity have been described in the last decade, some of which are currently undergoing clin. evaluation.  Here, I review the large preclin. effort to the development of specific RET inhibitors, including medicinal chem. analyses that may help refine potency and selectivity of future RET-targeted inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7NbIf0vPkuLVg90H21EOLACvtfcHk0ljAWofVqAvUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVWrt70%253D&md5=c67b95973706091ef5bd7d376a6bc090</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F092986711794088308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794088308%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520RET%2520kinase%2520inhibitors%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D162%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Matsui, J.; Minoshima, Y.; Tsuruoka, A.; Funahashi, Y.</span><span> </span><span class="NLM_article-title">Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition</span>.  <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">8, Suppl. 1</span>); Proceedings of the 101st Annual Meeting of AACR, Washington, DC, Apr 17–21, 2010; Abstract 3614.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&issue=8%2C+Suppl.+1&author=J.+Matsui&author=Y.+Minoshima&author=A.+Tsuruoka&author=Y.+Funahashi&title=Multi-targeted+kinase+inhibitor+E7080+showed+anti-tumor+activity+against+medullary+thyroid+carcinoma+and+squamous+thyroid+carcinoma+cell+line+based+on+RET+and+VEGFR2+tyrosine+kinase+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26atitle%3DMulti-targeted%2520kinase%2520inhibitor%2520E7080%2520showed%2520anti-tumor%2520activity%2520against%2520medullary%2520thyroid%2520carcinoma%2520and%2520squamous%2520thyroid%2520carcinoma%2520cell%2520line%2520based%2520on%2520RET%2520and%2520VEGFR2%2520tyrosine%2520kinase%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3D8%252C%2520Suppl.%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Schlumberger, M.; Tahara, M.; Wirth, L. J.; Robinson, B.; Brose, M. S.; Elisei, R.; Dutcus, C. E.; de las Heras, B.; Zhu, J.; Habra, M. A.; Newbold, K.; Shah, M. H.; Hoff, A. O.; Gianoukakis, A. G.; Kiyota, N.; Taylor, M. H.; Kim, S.-B.; Krzyzanowska, M. K.; Sherman, S. I.</span><span> </span><span class="NLM_article-title">A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup>I-refractory differentiated thyroid cancer (SELECT)</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span>; ASCO Annual Meeting Abstracts, No. 15_suppl (May 20 Supplement), 2014, LBA6008.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&author=M.+Schlumberger&author=M.+Tahara&author=L.+J.+Wirth&author=B.+Robinson&author=M.+S.+Brose&author=R.+Elisei&author=C.+E.+Dutcus&author=B.+de+las+Heras&author=J.+Zhu&author=M.+A.+Habra&author=K.+Newbold&author=M.+H.+Shah&author=A.+O.+Hoff&author=A.+G.+Gianoukakis&author=N.+Kiyota&author=M.+H.+Taylor&author=S.-B.+Kim&author=M.+K.+Krzyzanowska&author=S.+I.+Sherman&title=A+phase+3%2C+multicenter%2C+double-blind%2C+placebo-controlled+trial+of+lenvatinib+%28E7080%29+in+patients+with+131I-refractory+differentiated+thyroid+cancer+%28SELECT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchlumberger%26aufirst%3DM.%26atitle%3DA%2520phase%25203%252C%2520multicenter%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520lenvatinib%2520%2528E7080%2529%2520in%2520patients%2520with%2520131I-refractory%2520differentiated%2520thyroid%2520cancer%2520%2528SELECT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugi, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span> </span><span class="NLM_article-title">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.canlet.2013.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23856031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=97-103&author=K.+Okamotoauthor=K.+Kodamaauthor=K.+Takaseauthor=N.+H.+Sugiauthor=Y.+Yamamotoauthor=M.+Iwataauthor=A.+Tsuruoka&title=Antitumor+activities+of+the+targeted+multi-tyrosine+kinase+inhibitor+lenvatinib+%28E7080%29+against+RET+gene+fusion-driven+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span></div><div class="casAuthors">Okamoto, Kiyoshi; Kodama, Kotaro; Takase, Kazuma; Sugi, Naoko Hata; Yamamoto, Yuji; Iwata, Masao; Tsuruoka, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-103</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas.  Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clin. trials.  Here we evaluated lenvatinib in RET gene fusion-driven preclin. models.  In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET.  Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells.  These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr151nVk6WXn7Vg90H21EOLACvtfcHk0lixD1RHp3_yyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M&md5=e2399184aae74ae2c4b18997a6b7273b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKodama%26aufirst%3DK.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DSugi%26aufirst%3DN.%2BH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DTsuruoka%26aufirst%3DA.%26atitle%3DAntitumor%2520activities%2520of%2520the%2520targeted%2520multi-tyrosine%2520kinase%2520inhibitor%2520lenvatinib%2520%2528E7080%2529%2520against%2520RET%2520gene%2520fusion-driven%2520tumor%2520models%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D97%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitagliano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7284</span><span class="NLM_x">–</span> <span class="NLM_lpage">7290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=7284-7290&author=F.+Carlomagnoauthor=D.+Vitaglianoauthor=T.+Guidaauthor=F.+Ciardielloauthor=G.+Tortoraauthor=G.+Vecchioauthor=A.+J.+Ryanauthor=G.+Fontaniniauthor=A.+Fuscoauthor=M.+Santoro&title=ZD6474%2C+an+orally+available+inhibitor+of+KDR+tyrosine+kinase+activity%2C+efficiently+blocks+oncogenic+RET+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DFontanini%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DZD6474%252C%2520an%2520orally%2520available%2520inhibitor%2520of%2520KDR%2520tyrosine%2520kinase%2520activity%252C%2520efficiently%2520blocks%2520oncogenic%2520RET%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D7284%26epage%3D7290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjær, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibáñez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kj%C3%A6rauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0lixD1RHp3_yyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKj%25C3%25A6r%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Gautschi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebold, J.</span><span> </span><span class="NLM_article-title">A patient with lung adenocarcinoma and RET fusion treated with vandetanib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e43</span><span class="NLM_x">–</span> <span class="NLM_lpage">e44</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e43-e44&author=O.+Gautschiauthor=T.+Zanderauthor=F.+A.+Kellerauthor=K.+Strobelauthor=A.+Hirschmannauthor=S.+Aebiauthor=J.+Diebold&title=A+patient+with+lung+adenocarcinoma+and+RET+fusion+treated+with+vandetanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGautschi%26aufirst%3DO.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DKeller%26aufirst%3DF.%2BA.%26aulast%3DStrobel%26aufirst%3DK.%26aulast%3DHirschmann%26aufirst%3DA.%26aulast%3DAebi%26aufirst%3DS.%26aulast%3DDiebold%26aufirst%3DJ.%26atitle%3DA%2520patient%2520with%2520lung%2520adenocarcinoma%2520and%2520RET%2520fusion%2520treated%2520with%2520vandetanib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3De43%26epage%3De44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rha, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kweon, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shong, M.</span><span> </span><span class="NLM_article-title">An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">4070</span><span class="NLM_x">–</span> <span class="NLM_lpage">4076</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1210%2Fjc.2005-2845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=16849418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSjtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=4070-4076&author=D.+W.+Kimauthor=Y.+S.+Joauthor=H.+S.+Jungauthor=H.+K.+Chungauthor=J.+H.+Songauthor=K.+C.+Parkauthor=S.+H.+Parkauthor=J.+H.+Hwangauthor=S.+Y.+Rhaauthor=G.+R.+Kweonauthor=S.+J.+Leeauthor=K.+W.+Joauthor=M.+Shong&title=An+orally+administered+multitarget+tyrosine+kinase+inhibitor%2C+SU11248%2C+is+a+novel+potent+inhibitor+of+thyroid+oncogenic+RET%2Fpapillary+thyroid+cancer+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/Papillary thyroid cancer kinases</span></div><div class="casAuthors">Kim, Dong Wook; Jo, Young Suk; Jung, Hye Sook; Chung, Hyo Kyun; Song, Jung Hun; Park, Ki Cheol; Park, Su Hyeon; Hwang, Jung Hwan; Rha, So Young; Kweon, Gi Ryang; Lee, Su-Jae; Jo, Ki-Won; Shong, Minho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4070-4076</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Context: The oncogenic RET/PTC tyrosine kinase causes papillary thyroid cancer (PTC).  The use of inhibitors specific for RET/PTC may be useful for targeted therapy of PTC.  Objective: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC.  Design: SU11248, SU5416, and SU6668 were synthesized, and their inhibitory potencies were evaluated using an in vitro RET/PTC kinase assay.  The inhibitory effects of the compds. on RET/PTC were evaluated by quantifying the autophosphorylation of RET/PTC, signal transducer and activator of transcription (STAT)-3 activation, and the morphol. reversal of RET/PTC-transformed cells.  Results: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC50 of approx. 944 nM for SU5416, 562 nM for SU6668, and 224 nM for SU11248.  Thus, SU11248 effectively inhibits the kinase activity of RET/PTC3.  RET/PTC-mediated Y705 phosphorylation of STAT3 was inhibited by addn. of SU11248, and the inhibitory effects of SU11248 on the tyrosine phosphorylation and transcriptional activation of STAT3 were very closely correlated with decreased autophosphorylation of RET/PTC.  SU11248 caused a complete morphol. reversion of transformed NIH-RET/PTC3 cells and inhibited the growth of TPC-1 cells that have an endogenous RET/PTC1.  Conclusion: SU11248 is a highly effective tyrosine kinase inhibitor of the RET/PTC oncogenic kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbInzSrkRMBbVg90H21EOLACvtfcHk0ljZB_gIkjIv9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSjtbrN&md5=05214e9ce472b7c562d53f4d95a39cb0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1210%2Fjc.2005-2845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2005-2845%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DJo%26aufirst%3DY.%2BS.%26aulast%3DJung%26aufirst%3DH.%2BS.%26aulast%3DChung%26aufirst%3DH.%2BK.%26aulast%3DSong%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DK.%2BC.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BH.%26aulast%3DRha%26aufirst%3DS.%2BY.%26aulast%3DKweon%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DJo%26aufirst%3DK.%2BW.%26aulast%3DShong%26aufirst%3DM.%26atitle%3DAn%2520orally%2520administered%2520multitarget%2520tyrosine%2520kinase%2520inhibitor%252C%2520SU11248%252C%2520is%2520a%2520novel%2520potent%2520inhibitor%2520of%2520thyroid%2520oncogenic%2520RET%252Fpapillary%2520thyroid%2520cancer%2520kinases%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2006%26volume%3D91%26spage%3D4070%26epage%3D4076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S.</span><span> </span><span class="NLM_article-title">An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline</span> <span class="citation_source-journal">ASCO Meet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">5508</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=5508&author=P.+Schoffskiauthor=R.+Eliseiauthor=S.+Muller&title=An+international%2C+double-blind%2C+randomized%2C+placebo-controlled+phase+III+trial+%28EXAM%29+of+cabozantinib+%28XL184%29+in+medullary+thyroid+carcinoma+%28MTC%29+patients+with+documented+RECIST+progression+at+baseline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DS.%26atitle%3DAn%2520international%252C%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520phase%2520III%2520trial%2520%2528EXAM%2529%2520of%2520cabozantinib%2520%2528XL184%2529%2520in%2520medullary%2520thyroid%2520carcinoma%2520%2528MTC%2529%2520patients%2520with%2520documented%2520RECIST%2520progression%2520at%2520baseline%26jtitle%3DASCO%2520Meet.%26date%3D2012%26volume%3D34%26spage%3D5508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><div class="note"><p class="first last">The first paper to show clinical activity of a RET inhibitor in patients with <i>RET</i>-rearranged NSCLC, validating RET as a molecular target in lung cancer:</p></div><span class="NLM_contrib-group">Drilon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasanovic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suehara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizvi, N.</span><span> </span><span class="NLM_article-title">Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">630</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=630-635&author=A.+Drilonauthor=L.+Wangauthor=A.+Hasanovicauthor=Y.+Sueharaauthor=D.+Lipsonauthor=P.+Stephensauthor=J.+Rossauthor=V.+Millerauthor=M.+Ginsbergauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=N.+Rizvi&title=Response+to+cabozantinib+in+patients+with+RET+fusion-positive+lung+adenocarcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHasanovic%26aufirst%3DA.%26aulast%3DSuehara%26aufirst%3DY.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DGinsberg%26aufirst%3DM.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRizvi%26aufirst%3DN.%26atitle%3DResponse%2520to%2520cabozantinib%2520in%2520patients%2520with%2520RET%2520fusion-positive%2520lung%2520adenocarcinomas%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D630%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">De Falco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonocore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torregrossa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">E811</span><span class="NLM_x">–</span> <span class="NLM_lpage">E819</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=E811-E819&author=V.+De+Falcoauthor=P.+Buonocoreauthor=M.+Muthuauthor=L.+Torregrossaauthor=F.+Basoloauthor=M.+Billaudauthor=J.+M.+Gozgitauthor=F.+Carlomagnoauthor=M.+Santoro&title=Ponatinib+%28AP24534%29+is+a+novel+potent+inhibitor+of+oncogenic+RET+mutants+associated+with+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DBuonocore%26aufirst%3DP.%26aulast%3DMuthu%26aufirst%3DM.%26aulast%3DTorregrossa%26aufirst%3DL.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DPonatinib%2520%2528AP24534%2529%2520is%2520a%2520novel%2520potent%2520inhibitor%2520of%2520oncogenic%2520RET%2520mutants%2520associated%2520with%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3DE811%26epage%3DE819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x"> (</span><span class="NLM_issue">1–2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&issue=1%E2%80%932&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+potent+inhibitor+of+wild-type+and+drug-resistant+gatekeeper+mutant+RET+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0lgBiiAb4fq9GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520potent%2520inhibitor%2520of%2520wild-type%2520and%2520drug-resistant%2520gatekeeper%2520mutant%2520RET%2520kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Morgillo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orditura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vita, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciardiello, F.</span><span> </span><span class="NLM_article-title">Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e28841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e28841&author=F.+Morgilloauthor=E.+Martinelliauthor=T.+Troianiauthor=M.+Ordituraauthor=F.+De+Vitaauthor=F.+Ciardiello&title=Antitumor+activity+of+sorafenib+in+human+cancer+cell+lines+with+acquired+resistance+to+EGFR+and+VEGFR+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorgillo%26aufirst%3DF.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DTroiani%26aufirst%3DT.%26aulast%3DOrditura%26aufirst%3DM.%26aulast%3DDe%2BVita%26aufirst%3DF.%26aulast%3DCiardiello%26aufirst%3DF.%26atitle%3DAntitumor%2520activity%2520of%2520sorafenib%2520in%2520human%2520cancer%2520cell%2520lines%2520with%2520acquired%2520resistance%2520to%2520EGFR%2520and%2520VEGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De28841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magee, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Links, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstra, R. M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacke, C. M.</span><span> </span><span class="NLM_article-title">Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">29230</span><span class="NLM_x">–</span> <span class="NLM_lpage">29240</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=29230-29240&author=I.+Plaza-Menachoauthor=L.+Mologniauthor=E.+Salaauthor=C.+Gambacorti-Passeriniauthor=A.+I.+Mageeauthor=T.+P.+Linksauthor=R.+M.+W.+Hofstraauthor=D.+Barfordauthor=C.+M.+Isacke&title=Sorafenib+functions+to+potently+suppress+RET+tyrosine+kinase+activity+by+direct+enzymatic+inhibition+and+promoting+RET+lysosomal+degradation+independent+of+proteasomal+targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DSala%26aufirst%3DE.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMagee%26aufirst%3DA.%2BI.%26aulast%3DLinks%26aufirst%3DT.%2BP.%26aulast%3DHofstra%26aufirst%3DR.%2BM.%2BW.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DIsacke%26aufirst%3DC.%2BM.%26atitle%3DSorafenib%2520functions%2520to%2520potently%2520suppress%2520RET%2520tyrosine%2520kinase%2520activity%2520by%2520direct%2520enzymatic%2520inhibition%2520and%2520promoting%2520RET%2520lysosomal%2520degradation%2520independent%2520of%2520proteasomal%2520targeting%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D29230%26epage%3D29240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osgood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of motesanib in a medullary thyroid cancer model</span> <span class="citation_source-journal">J. Endocrinol. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=181-190&author=A.+Coxonauthor=J.+Breadyauthor=S.+Kaufmanauthor=J.+Estradaauthor=T.+Osgoodauthor=J.+Canonauthor=L.+Wangauthor=R.+Radinskyauthor=R.+Kendallauthor=P.+Hughesauthor=A.+Polverino&title=Anti-tumor+activity+of+motesanib+in+a+medullary+thyroid+cancer+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DPolverino%26aufirst%3DA.%26atitle%3DAnti-tumor%2520activity%2520of%2520motesanib%2520in%2520a%2520medullary%2520thyroid%2520cancer%2520model%26jtitle%3DJ.%2520Endocrinol.%2520Invest.%26date%3D2012%26volume%3D35%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span>Postgradute Cancer Research Symposium (at The University of Sydney, Nov<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>. <a href="http://sydney.edu.au/cancer-research/pdf/Final_Symposium_booklet.pdf" class="extLink">http://sydney.edu.au/cancer-research/pdf/Final_Symposium_booklet.pdf</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Postgradute+Cancer+Research+Symposium+%28at+The+University+of+Sydney%2C+Nov+2013%29+.+http%3A%2F%2Fsydney.edu.au%2Fcancer-research%2Fpdf%2FFinal_Symposium_booklet.pdf+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widemann, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuk, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitcomb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balis, F. M.</span><span> </span><span class="NLM_article-title">Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4239</span><span class="NLM_x">–</span> <span class="NLM_lpage">4248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1158%2F1078-0432.CCR-13-0071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23766359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4239-4248&author=E.+Foxauthor=B.+C.+Widemannauthor=M.+K.+Chukauthor=L.+J.+Marcusauthor=A.+Aikinauthor=P.+Whitcombauthor=M.+J.+Merinoauthor=M.+Lodishauthor=E.+Dombiauthor=S.+M.+Steinbergauthor=S.+A.+Wellsauthor=F.+M.+Balis&title=Vandetanib+in+children+and+adolescents+with+multiple+endocrine+neoplasia+type+2B+associated+medullary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma</span></div><div class="casAuthors">Fox, Elizabeth; Widemann, Brigitte C.; Chuk, Meredith K.; Marcus, Leigh; Aikin, Alberta; Whitcomb, Patricia O.; Merino, Maria J.; Lodish, Maya; Dombi, Eva; Steinberg, Seth M.; Wells, Samuel A.; Balis, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4239-4248</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET (REarranged during Transfection) proto-oncogene.  Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC.  Exptl. Design: We conducted a phase I/II trial of vandetanib for children (5-12 years) and adolescents (13-18 years) with MTC to define a recommended dose and assess antitumor activity.  The starting dose was 100 mg/m2 administered orally, once daily, continuously for 28-day treatment cycles.  The dose could be escalated to 150 mg/m2/d after two cycles.  Radiog. response to vandetanib was quantified using RECIST (v1.0), biomarker response was measured by comparing posttreatment serum calcitonin and carcinoembryonic antigen (CEA) levels to baseline, and a patient-reported outcome was used to assess clin. benefit.  Results: Sixteen patients with locally advanced or metastatic MTC received vandetanib for a median (range) 27 (2-52) cycles.  Eleven patients remain on protocol therapy.  Diarrhea was the primary dose-limiting toxicity.  In subjects with M918T RET germline mutations (n = 15) the confirmed objective partial response rate was 47% (exact 95% confidence intervals, 21%-75%).  Biomarker partial response was confirmed for calcitonin in 12 subjects and for CEA in 8 subjects.  Conclusion: Using an innovative trial design and selecting patients based on target gene expression, we conclude that vandetanib 100 mg/m2/d is a well-tolerated and highly active new treatment for children and adolescents with MEN2B and locally advanced or metastatic MTC.  Clin Cancer Res; 19(15); 4239-48. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptEqeEhvtU9rVg90H21EOLACvtfcHk0li-V1Fbu-fYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zN&md5=738e0cdf62786fbc0db45df19cfd3eaa</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0071%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DE.%26aulast%3DWidemann%26aufirst%3DB.%2BC.%26aulast%3DChuk%26aufirst%3DM.%2BK.%26aulast%3DMarcus%26aufirst%3DL.%2BJ.%26aulast%3DAikin%26aufirst%3DA.%26aulast%3DWhitcomb%26aufirst%3DP.%26aulast%3DMerino%26aufirst%3DM.%2BJ.%26aulast%3DLodish%26aufirst%3DM.%26aulast%3DDombi%26aufirst%3DE.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DBalis%26aufirst%3DF.%2BM.%26atitle%3DVandetanib%2520in%2520children%2520and%2520adolescents%2520with%2520multiple%2520endocrine%2520neoplasia%2520type%25202B%2520associated%2520medullary%2520thyroid%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4239%26epage%3D4248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+genetic+discovery+of+targets+and+anti-targets+for+cancer+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0li-V1Fbu-fYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520genetic%2520discovery%2520of%2520targets%2520and%2520anti-targets%2520for%2520cancer%2520polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D80%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+M%C3%BCllerauthor=P.+Sch%C3%B6ffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lgevaUiFNr9Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%2BP.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer</span> <span class="citation_source-journal">Oral Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.oraloncology.2013.03.442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23582411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1CgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=707-10&author=S.+I.+Sherman&title=Lessons+learned+and+questions+unanswered+from+use+of+multitargeted+kinase+inhibitors+in+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer</span></div><div class="casAuthors">Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Oral Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">707-710</span>CODEN:
                <span class="NLM_cas:coden">EJCCER</span>;
        ISSN:<span class="NLM_cas:issn">1368-8375</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To review studies of novel multitargeted kinase inhibitors studied in patients with medullary thyroid cancer (MTC).  Search of relevant refs. in PubMed and Google Scholar on "chemotherapy" and "medullary thyroid cancer".  Multitargeted kinase inhibitors have revolutionized the role of chemotherapy for progressive MTC, providing for the first time tolerable therapeutic options that can improve outcomes in patients with progressive disease.  Drugs thought to inhibit the RET kinase have advanced the furthest for this disease, but these agents also target the VEGF receptor along with other kinases that may be relevant to both beneficial and adverse effects.  Vandetanib improved progression-free survival from 19.3 to 30.5 mo compared with placebo in patients with metastatic disease, whereas cabozantinib improved progression-free survival from 4.0 mo to 11.2 mo in a population with more aggressive disease.  However, "cure" remains elusive, adverse events frequent, and exactly how such "targeted" agents actually function within MTC remains unclear.  New approaches to clin. trial design and the preclin. development of targeted agents may be required to optimize the combination of max. efficacy with minimal toxicity for patients with metastatic MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLAgDadLtuY7Vg90H21EOLACvtfcHk0lgevaUiFNr9Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1CgtLc%253D&md5=1de31be1f7b2c85a0b1aba7c9210fd5d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.oraloncology.2013.03.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oraloncology.2013.03.442%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DLessons%2520learned%2520and%2520questions%2520unanswered%2520from%2520use%2520of%2520multitargeted%2520kinase%2520inhibitors%2520in%2520medullary%2520thyroid%2520cancer%26jtitle%3DOral%2520Oncol.%26date%3D2013%26volume%3D49%26spage%3D707%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Houvras, Y.</span><span> </span><span class="NLM_article-title">Completing the arc: targeted inhibition of RET in medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2011.38.7639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22162569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFGrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=200-202&author=Y.+Houvras&title=Completing+the+arc%3A+targeted+inhibition+of+RET+in+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Completing the Arc: targeted inhibition of RET in medullary thyroid cancer</span></div><div class="casAuthors">Houvras, Yariv</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-202</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Wells et al. (2012) entitled 'Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial' is reviewed with commentary and refs.  These authors present the results of the ZETA (Zactima Efficacy in Thyroid Cancer Assessment) trial, a phase III randomized, double-blind, placebo-controlled trial of vandetanib in patients with sporadic and hereditary medullary thyroid cancer (MTC).  Vandetanib (formerly ZD6474) is a small-mol. tyrosine kinase inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor (VEGFR) kinases.  In ZETA, patients with advanced MTC who were randomly assigned to treatment with vandetanib had significantly longer progression-free survival than those randomly assigned to treatment with placebo.  The results of the ZETA trial led the US Food and Drug Administration to approve vandetanib for treatment of symptomatic or progressive MTC earlier this year.  This is the first drug approved for MTC and the first TKI approved for any thyroid cancer indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU1hxYPMJuxbVg90H21EOLACvtfcHk0lhkiGfyPnXrHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFGrtr0%253D&md5=9a0cd65f556a9a573030eb4aea37ddf9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.38.7639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.38.7639%26sid%3Dliteratum%253Aachs%26aulast%3DHouvras%26aufirst%3DY.%26atitle%3DCompleting%2520the%2520arc%253A%2520targeted%2520inhibition%2520of%2520RET%2520in%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D200%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Wells, S. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dralle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasselli, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmuir, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span> </span><span class="NLM_article-title">Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2011.35.5040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22025146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=134-141&author=S.+A.+Wellsauthor=B.+G.+Robinsonauthor=R.+F.+Gagelauthor=H.+Dralleauthor=J.+A.+Faginauthor=M.+Santoroauthor=E.+Baudinauthor=R.+Eliseiauthor=B.+Jarzabauthor=J.+R.+Vasselliauthor=J.+Readauthor=P.+Langmuirauthor=A.+J.+Ryanauthor=M.+J.+Schlumberger&title=Vandetanib+in+patients+with+locally+advanced+or+metastatic+medullary+thyroid+cancer%3A+a+randomized%2C+double-blind+phase+III+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</span></div><div class="casAuthors">Wells, Samuel A., Jr.; Robinson, Bruce G.; Gagel, Robert F.; Dralle, Henning; Fagin, James A.; Santoro, Massimo; Baudin, Eric; Elisei, Rossella; Jarzab, Barbara; Vasselli, James R.; Read, Jessica; Langmuir, Peter; Ryan, Anderson J.; Schlumberger, Martin I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC).  Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.  Patients and Methods Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo.  On objective disease progression, patients could elect to receive open-label vandetanib.  The primary end point was progression-free survival (PFS), detd. by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.  Results Between Dec. 2006 and Nov. 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100).  At data cutoff (July 2009; median follow-up, 24 mo), 37% of patients had progressed and 15% had died.  The study met its primary objective of PFS prolongation with vandetanib vs. placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001).  Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochem. response (P < .001).  Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65).  A final survival anal. will take place when 50% of the patients have died.  Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).  Conclusion Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnzd5Ld1n-AbVg90H21EOLACvtfcHk0lhkiGfyPnXrHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D&md5=99ea5fa9e2cd53b14f85b8a37e1e3c2b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5040%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DDralle%26aufirst%3DH.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DBaudin%26aufirst%3DE.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DVasselli%26aufirst%3DJ.%2BR.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DLangmuir%26aufirst%3DP.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26atitle%3DVandetanib%2520in%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520medullary%2520thyroid%2520cancer%253A%2520a%2520randomized%252C%2520double-blind%2520phase%2520III%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D134%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forastiere, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janisch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nauling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2660</span><span class="NLM_x">–</span> <span class="NLM_lpage">2666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2010.32.4145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=21606412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2660-2666&author=R.+Kurzrockauthor=S.+I.+Shermanauthor=D.+W.+Ballauthor=A.+A.+Forastiereauthor=R.+B.+Cohenauthor=R.+Mehraauthor=D.+G.+Pfisterauthor=E.+E.+Cohenauthor=L.+Janischauthor=F.+Naulingauthor=D.+S.+Hongauthor=C.+S.+Ngauthor=L.+Yeauthor=R.+F.+Gagelauthor=J.+Fryeauthor=T.+M%C3%BCllerauthor=M.+J.+Ratainauthor=R.+Salgia&title=Activity+of+XL184+%28cabozantinib%29%2C+an+oral+tyrosine+kinase+inhibitor%2C+in+patients+with+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer</span></div><div class="casAuthors">Kurzrock, Razelle; Sherman, Steven I.; Ball, Douglas W.; Forastiere, Arlene A.; Cohen, Roger B.; Mehra, Ranee; Pfister, David G.; Cohen, Ezra E. W.; Janisch, Linda; Nauling, Forlisa; Hong, David S.; Ng, Chaan S.; Ye, Lei; Gagel, Robert F.; Frye, John; Muller, Thomas; Ratain, Mark J.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2660-2666</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclin. models.  Early observations of clin. benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article.  Patients and Methods: A phase I dose-escalation study of oral cabozantinib was conducted in patients with advanced solid tumors.  Primary end points included evaluation of safety, pharmacokinetics, and max.-tolerated dose (MTD) detn.  Addnl. end points included RECIST (Response Evaluation Criteria in Solid Tumors) response, pharmacodynamics, RET mutational status, and biomarker analyses.  Results: Eighty-five patients were enrolled, including 37 with MTC.  The MTD was 175 mg daily.  Dose-limiting toxicities were grade 3 palmar plantar erythrodysesthesia (PPE), mucositis, and AST, ALT, and lipase elevations and grade 2 mucositis that resulted in dose interruption and redn.  Ten (29%) of 35 patients with MTC with measurable disease had a confirmed partial response.  Overall, 18 patients experienced tumor shrinkage of 30% or more, including 17 (49%) of 35 patients with MTC with measurable disease.  Addnl., 15 (41%) of 37 patients with MTC had stable disease (SD) for at least 6 mo, resulting in SD for 6 mo or longer or confirmed partial response in 68% of patients with MTC.  Conclusion: Cabozantinib has an acceptable safety profile and is active in MTC.  Cabozantinib may provide clin. benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and RET.  A global phase III pivotal study in MTC is ongoing (ClinicalTrials.gov no. NCT00215605).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqsQ7UriHpu7Vg90H21EOLACvtfcHk0liBW2ujQUOKPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbY%253D&md5=01614c45ab0e9fb3afff120e8e94e4bf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.32.4145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.32.4145%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26aulast%3DBall%26aufirst%3DD.%2BW.%26aulast%3DForastiere%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DPfister%26aufirst%3DD.%2BG.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DJanisch%26aufirst%3DL.%26aulast%3DNauling%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DNg%26aufirst%3DC.%2BS.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DFrye%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DActivity%2520of%2520XL184%2520%2528cabozantinib%2529%252C%2520an%2520oral%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2660%26epage%3D2666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Blencke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span> </span><span class="NLM_article-title">Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.chembiol.2004.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=15157880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=691-701&author=S.+Blenckeauthor=B.+Zechauthor=O.+Engkvistauthor=Z.+Greffauthor=L.+Orfiauthor=Z.+Horvathauthor=G.+Keriauthor=A.+Ullrichauthor=H.+Daub&title=Characterization+of+a+conserved+structural+determinant+controlling+protein+kinase+sensitivity+to+selective+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors</span></div><div class="casAuthors">Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Some protein kinases are known to acquire resistance to selective small mol. inhibitors upon mutation of a conserved threonine at the ATP binding site to a larger residue.  Here, we performed a comprehensive mutational anal. of this structural element and detd. the cellular sensitivities of several disease-relevant tyrosine kinases against various inhibitors.  Mutant kinases possessing a larger side chain at the crit. site showed resistance to most compds. tested, such as ZD1839, PP1, AG1296, STI571, and a pyrido[2,3-d]pyrimidine inhibitor.  In contrast, indolinones affected both wild-type and mutant kinases with similar potencies.  Resistant mutants were established for pharmacol. anal. of βPDGF receptor-mediated signaling and allowed the generation of a drug-inducible system of cellular Src kinase activity.  Our data establish a conserved structural determinant of protein kinase sensitivity relevant for both signal transduction research and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWLToAufPZDbVg90H21EOLACvtfcHk0liBW2ujQUOKPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D&md5=3224f7453efd9b60f5102e300d195aa0</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DBlencke%26aufirst%3DS.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DDaub%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520a%2520conserved%2520structural%2520determinant%2520controlling%2520protein%2520kinase%2520sensitivity%2520to%2520selective%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D691%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witucki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=1219-1226&author=Y.+Liuauthor=K.+Shahauthor=F.+Yangauthor=L.+Wituckiauthor=K.+M.+Shokat&title=A+molecular+gate+which+controls+unnatural+ATP+analogue+recognition+by+the+tyrosine+kinase+v-Src"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DWitucki%26aufirst%3DL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520molecular%2520gate%2520which%2520controls%2520unnatural%2520ATP%2520analogue%2520recognition%2520by%2520the%2520tyrosine%2520kinase%2520v-Src%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1998%26volume%3D6%26spage%3D1219%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Bishop, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubersax, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petsch, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheos, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blethrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsien, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A chemical switch for inhibitor-sensitive alleles of any protein kinase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2F35030148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=11014197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2ntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=395-401&author=A.+C.+Bishopauthor=J.+A.+Ubersaxauthor=D.+T.+Petschauthor=D.+P.+Matheosauthor=N.+S.+Grayauthor=J.+Blethrowauthor=E.+Shimizuauthor=J.+Z.+Tsienauthor=P.+G.+Schultzauthor=M.+D.+Roseauthor=J.+L.+Woodauthor=D.+O.+Morganauthor=K.+M.+Shokat&title=A+chemical+switch+for+inhibitor-sensitive+alleles+of+any+protein+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A chemical switch for inhibitor-sensitive alleles of any protein kinase</span></div><div class="casAuthors">Bishop, Anthony C.; Ubersax, Jeffrey A.; Petsch, Dejah T.; Matheos, Dina P.; Gray, Nathanael S.; Blethrow, Justin; Shimizu, Eiji; Tsien, Joe Z.; Schultz, Peter G.; Rose, Mark D.; Wood, John L.; Morgan, David O.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6802</span>),
    <span class="NLM_cas:pages">395-401</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases have proved to be largely resistant to the design of highly specific inhibitors, even with the aid of combinatorial chem.  The lack of these reagents has complicated efforts to assign specific signaling roles to individual kinases.  Here we describe a chem. genetic strategy for sensitizing protein kinases to cell-permeable mols. that do not inhibit wild-type kinases.  From two inhibitor scaffolds, we have identified potent and selective inhibitors for sensitized kinases from five distinct subfamilies.  Tyrosine and serine/threonine kinases are equally amenable to this approach.  We have analyzed a budding yeast strain carrying an inhibitor-sensitive form of the cyclin-dependent kinase Cdc28 (CDK1) in place of the wild-type protein.  Specific inhibition of Cdc28 in vivo caused a pre-mitotic cell-cycle arrest that is distinct from the G1 arrest typically obsd. in temp.-sensitive cdc28 mutants.  The mutation that confers inhibitor-sensitivity is easily identifiable from primary sequence alignments.  Thus, this approach can be used to systematically generate conditional alleles of protein kinases, allowing for rapid functional characterization of members of this important gene family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqipYQXO52a6rVg90H21EOLACvtfcHk0li9cxgOz2lUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2ntL4%253D&md5=736782d1116a86dfc0dd6ab9a9aeec0a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2F35030148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35030148%26sid%3Dliteratum%253Aachs%26aulast%3DBishop%26aufirst%3DA.%2BC.%26aulast%3DUbersax%26aufirst%3DJ.%2BA.%26aulast%3DPetsch%26aufirst%3DD.%2BT.%26aulast%3DMatheos%26aufirst%3DD.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DBlethrow%26aufirst%3DJ.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DTsien%26aufirst%3DJ.%2BZ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DRose%26aufirst%3DM.%2BD.%26aulast%3DWood%26aufirst%3DJ.%2BL.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520chemical%2520switch%2520for%2520inhibitor-sensitive%2520alleles%2520of%2520any%2520protein%2520kinase%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D395%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span> </span><span class="NLM_article-title">ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S6</span><span class="NLM_x">–</span> <span class="NLM_lpage">S13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=S6-S13&issue=Suppl.+1&author=A.+J.+Ryanauthor=S.+R.+Wedge&title=ZD6474%E2%80%94a+novel+inhibitor+of+VEGFR+and+EGFR+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26atitle%3DZD6474%25E2%2580%2594a%2520novel%2520inhibitor%2520of%2520VEGFR%2520and%2520EGFR%2520tyrosine%2520kinase%2520activity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26issue%3DSuppl.%25201%26spage%3DS6%26epage%3DS13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaganti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6056</span><span class="NLM_x">–</span> <span class="NLM_lpage">6063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6056-6063&author=F.+Carlomagnoauthor=T.+Guitaauthor=S.+Anagantiauthor=G.+Vecchioauthor=A.+Fuscoauthor=A.+J.+Ryanauthor=M.+Billaudauthor=M.+Santoro&title=Disease+associated+mutations+at+valine+804+in+the+RET+receptor+tyrosine+kinase+confer+resistance+to+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DGuita%26aufirst%3DT.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DDisease%2520associated%2520mutations%2520at%2520valine%2520804%2520in%2520the%2520RET%2520receptor%2520tyrosine%2520kinase%2520confer%2520resistance%2520to%2520selective%2520kinase%2520inhibitors%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6056%26epage%3D6063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer</span> <span class="citation_source-journal">J. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1179%2Fjoc.2004.16.Supplement-1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=15693160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFantb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=49-51&issue=Suppl.+1&author=F.+Carlomagnoauthor=M.+Santoro&title=Identification+of+RET+kinase+inhibitors+as+potential+new+treatment+for+sporadic+and+inherited+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer</span></div><div class="casAuthors">Carlomagno, F.; Santoro, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemotherapy (Firenze, Italy)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">49-51</span>CODEN:
                <span class="NLM_cas:coden">JCHEEU</span>;
        ISSN:<span class="NLM_cas:issn">1120-009X</span>.
    
            (<span class="NLM_cas:orgname">E.S.I.F.T. srl</span>)
        </div><div class="casAbstract">A review.  The RET gene is frequently mutated in papillary thyroid carcinoma and in medullary thyroid carcinoma.  We have identified three different anti-RET drugs: two pyrazolo-pyrimidines, PP1 and PP2 and an anilinoquinazoline, ZD6474 (AstraZeneca).  These compds. are able to inhibit RET kinase activity in vitro (IC50 dose 100 nM) and in vivo and they can prevent RET mediated transformation.  Finally, mutation of RET V804 to methionine or leucine, found in MTC patients, induces resistance to the three drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBTHWsZ79LB7Vg90H21EOLACvtfcHk0li9cxgOz2lUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFantb4%253D&md5=7ea950a62eb1a85019f6939616064eba</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1179%2Fjoc.2004.16.Supplement-1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1179%252Fjoc.2004.16.Supplement-1.49%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520RET%2520kinase%2520inhibitors%2520as%2520potential%2520new%2520treatment%2520for%2520sporadic%2520and%2520inherited%2520thyroid%2520cancer%26jtitle%3DJ.%2520Chemother.%26date%3D2004%26volume%3D16%26issue%3DSuppl.%25201%26spage%3D49%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Dinér, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alao, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Söderlund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunnerhagen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grøtli, M.</span><span> </span><span class="NLM_article-title">Preparation of 3-substituted-1-isopropyl-1<i>H</i>-pyrazole[3,4-<i>d</i>]pyrimidin-4-amines as RET kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4876</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003944" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4872-4876&author=P.+Din%C3%A9rauthor=J.+P.+Alaoauthor=J.+S%C3%B6derlundauthor=P.+Sunnerhagenauthor=M.+Gr%C3%B8tli&title=Preparation+of+3-substituted-1-isopropyl-1H-pyrazole%5B3%2C4-d%5Dpyrimidin-4-amines+as+RET+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm3003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003944%26sid%3Dliteratum%253Aachs%26aulast%3DDin%25C3%25A9r%26aufirst%3DP.%26aulast%3DAlao%26aufirst%3DJ.%2BP.%26aulast%3DS%25C3%25B6derlund%26aufirst%3DJ.%26aulast%3DSunnerhagen%26aufirst%3DP.%26aulast%3DGr%25C3%25B8tli%26aufirst%3DM.%26atitle%3DPreparation%2520of%25203-substituted-1-isopropyl-1H-pyrazole%255B3%252C4-d%255Dpyrimidin-4-amines%2520as%2520RET%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4872%26epage%3D4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Grieco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlingieri, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donghi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongarzone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Porta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span> </span><span class="NLM_article-title">PTC is a novel rearranged form of the <i>RET</i> proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">563</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1990&pages=557-563&author=M.+Griecoauthor=M.+Santoroauthor=M.+T.+Berlingieriauthor=R.+M.+Melilloauthor=R.+Donghiauthor=I.+Bongarzoneauthor=M.+A.+Pierottiauthor=G.+Della+Portaauthor=A.+Fuscoauthor=G.+Vecchio&title=PTC+is+a+novel+rearranged+form+of+the+RET+proto-oncogene+and+is+frequently+detected+in+vivo+in+human+thyroid+papillary+carcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrieco%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DBerlingieri%26aufirst%3DM.%2BT.%26aulast%3DMelillo%26aufirst%3DR.%2BM.%26aulast%3DDonghi%26aufirst%3DR.%26aulast%3DBongarzone%26aufirst%3DI.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DDella%2BPorta%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DVecchio%26aufirst%3DG.%26atitle%3DPTC%2520is%2520a%2520novel%2520rearranged%2520form%2520of%2520the%2520RET%2520proto-oncogene%2520and%2520is%2520frequently%2520detected%2520in%2520vivo%2520in%2520human%2520thyroid%2520papillary%2520carcinomas%26jtitle%3DCell%26date%3D1990%26volume%3D60%26spage%3D557%26epage%3D563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">ALKoma: a cancer subtype with a shared target</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=495-502&author=H.+Mano&title=ALKoma%3A+a+cancer+subtype+with+a+shared+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DALKoma%253A%2520a%2520cancer%2520subtype%2520with%2520a%2520shared%2520target%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D495%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0liKQIEnFHNMqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0liDD6eC2NI9vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Kohno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakaoku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span> </span><span class="NLM_article-title">RET fusion gene: translation to personalized lung cancer therapy</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=1396-1400&author=T.+Kohnoauthor=K.+Tsutaauthor=K.+Tsuchiharaauthor=T.+Nakaokuauthor=K.+Yohauthor=K.+Goto&title=RET+fusion+gene%3A+translation+to+personalized+lung+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DTsuchihara%26aufirst%3DK.%26aulast%3DNakaoku%26aufirst%3DT.%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26atitle%3DRET%2520fusion%2520gene%253A%2520translation%2520to%2520personalized%2520lung%2520cancer%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D104%26spage%3D1396%26epage%3D1400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span>Overview of Targeted Therapies for Cancer. <a href="http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/" class="extLink">http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Overview+of+Targeted+Therapies+for+Cancer.+http%3A%2F%2Fwww.mycancergenome.org%2Fcontent%2Fother%2Fmolecular-medicine%2Foverview-of-targeted-therapies-for-cancer%2F+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 32 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Casey J. N. Mathison, Donatella Chianelli, Paul V. Rucker, John Nelson, Jason Roland, Zhihong Huang, Yang Yang, Jiqing Jiang, Yun Feng Xie, Robert Epple, Badry Bursulaya, Christian Lee, Mu-Yun Gao, Jennifer Shaffer, Sergio Briones, Yelena Sarkisova, Anna Galkin, Lintong Li, Nanxin Li, Chun Li, Su Hua, Shailaja Kasibhatla, Jacqueline Kinyamu-Akunda, Rie Kikkawa, Valentina Molteni, <span class="NLM_string-name hlFld-ContribAuthor">John E. Tellew</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (4)
                                     , 558-565. <a href="https://doi.org/10.1021/acsmedchemlett.0c00015" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00015%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEfficacy%252Band%252BTolerability%252Bof%252BPyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252BRET%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BLung%252BAdenocarcinoma%26aulast%3DMathison%26aufirst%3DCasey%2BJ.%2BN.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10012020%26date%3D12022020%26date%3D19022020%26date%3D12022020%26volume%3D11%26issue%3D4%26spage%3D558%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hojong  Yoon</span>, <span class="hlFld-ContribAuthor ">Yeonui  Kwak</span>, <span class="hlFld-ContribAuthor ">Seunghye  Choi</span>, <span class="hlFld-ContribAuthor ">Hanna  Cho</span>, <span class="hlFld-ContribAuthor ">Nam Doo  Kim</span>, and <span class="hlFld-ContribAuthor ">Taebo  Sim</span>  . </span><span class="cited-content_cbyCitation_article-title">A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 358-373. <a href="https://doi.org/10.1021/acs.jmedchem.5b01522" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01522%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amine%252BDerivative%252BContaining%252Ban%252BIsoxazole%252BMoiety%252BIs%252Ba%252BSelective%252Band%252BPotent%252BInhibitor%252Bof%252BRET%252BGatekeeper%252BMutants%26aulast%3DYoon%26aufirst%3DHojong%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D30092015%26date%3D22122015%26date%3D14012016%26date%3D10122015%26volume%3D59%26issue%3D1%26spage%3D358%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghu  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Xin</span>, <span class="hlFld-ContribAuthor ">Biligetu  Pa</span>, <span class="hlFld-ContribAuthor ">Xiang  He</span>, <span class="hlFld-ContribAuthor ">Wenqiang  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor activity of sacroflavonoside. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Research</span><span> <strong>2021,</strong> <em>35 </em>
                                    (8)
                                     , 1292-1298. <a href="https://doi.org/10.1080/14786419.2019.1645660" title="DOI URL">https://doi.org/10.1080/14786419.2019.1645660</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14786419.2019.1645660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14786419.2019.1645660%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Research%26atitle%3DSynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bsacroflavonoside%26aulast%3DWang%26aufirst%3DQinghu%26date%3D2021%26date%3D2019%26volume%3D35%26issue%3D8%26spage%3D1292%26epage%3D1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lixian  Ding</span>, <span class="hlFld-ContribAuthor ">Bin  Li</span>, <span class="hlFld-ContribAuthor ">Xiaotong  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongsheng  Li</span>, <span class="hlFld-ContribAuthor ">Xinglong  Li</span>, <span class="hlFld-ContribAuthor ">Shuwei  Dang</span>, <span class="hlFld-ContribAuthor ">Qiang  Lv</span>, <span class="hlFld-ContribAuthor ">Jiufeng  Wei</span>, <span class="hlFld-ContribAuthor ">Haixia  Sun</span>, <span class="hlFld-ContribAuthor ">Hongsheng  Chen</span>, <span class="hlFld-ContribAuthor ">Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Guodong  Li</span>. </span><span class="cited-content_cbyCitation_article-title">KIF15 facilitates gastric cancer via enhancing proliferation, inhibiting apoptosis, and predict poor prognosis. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell International</span><span> <strong>2020,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12935-020-01199-7" title="DOI URL">https://doi.org/10.1186/s12935-020-01199-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12935-020-01199-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12935-020-01199-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%2520International%26atitle%3DKIF15%252Bfacilitates%252Bgastric%252Bcancer%252Bvia%252Benhancing%252Bproliferation%25252C%252Binhibiting%252Bapoptosis%25252C%252Band%252Bpredict%252Bpoor%252Bprognosis%26aulast%3DDing%26aufirst%3DLixian%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Young Kwang  Chae</span>, <span class="hlFld-ContribAuthor ">Pedro  Viveiros</span>, <span class="hlFld-ContribAuthor ">Caio T.  Heleno</span>, <span class="hlFld-ContribAuthor ">Haris  Bilal</span>, <span class="hlFld-ContribAuthor ">Bhoomika A.  Sukhadia</span>, <span class="hlFld-ContribAuthor ">Michael S.  Oh</span>, <span class="hlFld-ContribAuthor ">Muhamad Mubbashir  Sheikh</span>, <span class="hlFld-ContribAuthor ">Wade T.  Iams</span>, <span class="hlFld-ContribAuthor ">Lee Chun  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Cabozantinib in a Patient With
              EGFR
              -Mutated Non–Small-Cell Lung Cancer Harboring Acquired
              CCDC6-RET
              Fusion. </span><span class="cited-content_cbyCitation_journal-name">JCO Precision Oncology</span><span> <strong>2019,</strong> <em> </em>
                                    (3)
                                     , 1-5. <a href="https://doi.org/10.1200/PO.18.00295" title="DOI URL">https://doi.org/10.1200/PO.18.00295</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/PO.18.00295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FPO.18.00295%26sid%3Dliteratum%253Aachs%26jtitle%3DJCO%2520Precision%2520Oncology%26atitle%3DUse%252Bof%252BCabozantinib%252Bin%252Ba%252BPatient%252BWith%252BEGFR%252B-Mutated%252BNon%2525E2%252580%252593Small-Cell%252BLung%252BCancer%252BHarboring%252BAcquired%252BCCDC6-RET%252BFusion%26aulast%3DChae%26aufirst%3DYoung%2BKwang%26date%3D2019%26issue%3D3%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Modi  Wang</span>, <span class="hlFld-ContribAuthor ">N.  Naganna</span>, <span class="hlFld-ContribAuthor ">Herman O.  Sintim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>90 </em>, 103052. <a href="https://doi.org/10.1016/j.bioorg.2019.103052" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103052%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnicotinamide%252Baminonaphthyridine%252Bcompounds%252Bas%252Bpotent%252BRET%252Bkinase%252Binhibitors%252Band%252Bantitumor%252Bactivities%252Bagainst%252BRET%252Brearranged%252Blung%252Badenocarcinoma%26aulast%3DWang%26aufirst%3DModi%26date%3D2019%26volume%3D90%26spage%3D103052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen</span>, <span class="hlFld-ContribAuthor ">Guo</span>, <span class="hlFld-ContribAuthor ">Ma</span>, <span class="hlFld-ContribAuthor ">Chen</span>, <span class="hlFld-ContribAuthor ">Fan</span>, <span class="hlFld-ContribAuthor ">Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (16)
                                     , 2950. <a href="https://doi.org/10.3390/molecules24162950" title="DOI URL">https://doi.org/10.3390/molecules24162950</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24162950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24162950%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BN-Acylhydrazone%252BBond%252BLinked%252BHeterobivalent%252B%2525CE%2525B2-Carbolines%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DChen%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D16%26spage%3D2950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Da-Wei  Tian</span>, <span class="hlFld-ContribAuthor ">Zhou-Liang  Wu</span>, <span class="hlFld-ContribAuthor ">Li-Ming  Jiang</span>, <span class="hlFld-ContribAuthor ">Jie  Gao</span>, <span class="hlFld-ContribAuthor ">Chang-Li  Wu</span>, <span class="hlFld-ContribAuthor ">Hai-Long  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">KIF5A Promotes Bladder Cancer Proliferation
              In Vitro
              and
              In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Disease Markers</span><span> <strong>2019,</strong> <em>2019 </em>, 1-9. <a href="https://doi.org/10.1155/2019/4824902" title="DOI URL">https://doi.org/10.1155/2019/4824902</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2019/4824902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2019%2F4824902%26sid%3Dliteratum%253Aachs%26jtitle%3DDisease%2520Markers%26atitle%3DKIF5A%252BPromotes%252BBladder%252BCancer%252BProliferation%252BIn%252BVitro%252Band%252BIn%252BVivo%26aulast%3DTian%26aufirst%3DDa-Wei%26date%3D2019%26volume%3D2019%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Liu</span>, <span class="hlFld-ContribAuthor ">Tao  Shen</span>, <span class="hlFld-ContribAuthor ">Blaine H M  Mooers</span>, <span class="hlFld-ContribAuthor ">Frank  Hilberg</span>, <span class="hlFld-ContribAuthor ">Jie  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Drug resistance profiles of mutations in the RET kinase domain. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2018,</strong> <em>175 </em>
                                    (17)
                                     , 3504-3515. <a href="https://doi.org/10.1111/bph.14395" title="DOI URL">https://doi.org/10.1111/bph.14395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14395%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDrug%252Bresistance%252Bprofiles%252Bof%252Bmutations%252Bin%252Bthe%252BRET%252Bkinase%252Bdomain%26aulast%3DLiu%26aufirst%3DXuan%26date%3D2018%26date%3D2018%26volume%3D175%26issue%3D17%26spage%3D3504%26epage%3D3515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Valentino</span>, <span class="hlFld-ContribAuthor ">Gloria  Borra</span>, <span class="hlFld-ContribAuthor ">Paolo  Allione</span>, <span class="hlFld-ContribAuthor ">Lorena  Rossi</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging targets in advanced non-small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (13s)
                                     , 61-72. <a href="https://doi.org/10.2217/fon-2018-0099" title="DOI URL">https://doi.org/10.2217/fon-2018-0099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2018-0099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2018-0099%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DEmerging%252Btargets%252Bin%252Badvanced%252Bnon-small-cell%252Blung%252Bcancer%26aulast%3DValentino%26aufirst%3DFrancesco%26date%3D2018%26volume%3D14%26issue%3D13s%26spage%3D61%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeong- Oh  Kim</span>, <span class="hlFld-ContribAuthor ">Jung -Young  Shin</span>, <span class="hlFld-ContribAuthor ">Min Young  Kim</span>, <span class="hlFld-ContribAuthor ">Kyoung Hwa  Son</span>, <span class="hlFld-ContribAuthor ">Chan Kwon  Jung</span>, <span class="hlFld-ContribAuthor ">Tae-Jung  Kim</span>, <span class="hlFld-ContribAuthor ">Su Young  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Kil  Park</span>, <span class="hlFld-ContribAuthor ">Sook Whan  Sung</span>, <span class="hlFld-ContribAuthor ">Sang Ju  Bae</span>, <span class="hlFld-ContribAuthor ">Hyun Jung  Min</span>, <span class="hlFld-ContribAuthor ">Jin- Hyoung  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients. </span><span class="cited-content_cbyCitation_journal-name">Surgical Oncology</span><span> <strong>2018,</strong> <em>27 </em>
                                    (1)
                                     , 106-113. <a href="https://doi.org/10.1016/j.suronc.2018.01.006" title="DOI URL">https://doi.org/10.1016/j.suronc.2018.01.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.suronc.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.suronc.2018.01.006%26sid%3Dliteratum%253Aachs%26jtitle%3DSurgical%2520Oncology%26atitle%3DDetection%252Bof%252BRET%252B%252528rearranged%252Bduring%252Btransfection%252529%252Bvariants%252Band%252Btheir%252Bdownstream%252Bsignal%252Bmolecules%252Bin%252BRET%252Brearranged%252Blung%252Badenocarcinoma%252Bpatients%26aulast%3DKim%26aufirst%3DJeong-%2BOh%26date%3D2018%26volume%3D27%26issue%3D1%26spage%3D106%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>, <span class="hlFld-ContribAuthor ">Abdollah  Sadeghi-Nejad</span>. </span><span class="cited-content_cbyCitation_article-title">Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2018,</strong> <em>128 </em>, 1-17. <a href="https://doi.org/10.1016/j.phrs.2017.12.021" title="DOI URL">https://doi.org/10.1016/j.phrs.2017.12.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2017.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2017.12.021%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DRole%252Bof%252BRET%252Bprotein-tyrosine%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btreatment%252BRET-driven%252Bthyroid%252Band%252Blung%252Bcancers%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2018%26volume%3D128%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberto  Ferrara</span>, <span class="hlFld-ContribAuthor ">Nathalie  Auger</span>, <span class="hlFld-ContribAuthor ">Edouard  Auclin</span>, <span class="hlFld-ContribAuthor ">Benjamin  Besse</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (1)
                                     , 27-45. <a href="https://doi.org/10.1016/j.jtho.2017.10.021" title="DOI URL">https://doi.org/10.1016/j.jtho.2017.10.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2017.10.021%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DClinical%252Band%252BTranslational%252BImplications%252Bof%252BRET%252BRearrangements%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DFerrara%26aufirst%3DRoberto%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D27%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiping  Shi</span>, <span class="hlFld-ContribAuthor ">Bonan  Lai</span>, <span class="hlFld-ContribAuthor ">Shizhen  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jing  Nie</span>, <span class="hlFld-ContribAuthor ">Jun-An  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Synthesis of Novel Perfluorocarbon-Modulated 4-Anilinoquinazoline Analogues. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2017,</strong> <em>35 </em>
                                    (11)
                                     , 1693-1700. <a href="https://doi.org/10.1002/cjoc.201700240" title="DOI URL">https://doi.org/10.1002/cjoc.201700240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.201700240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.201700240%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DFacile%252BSynthesis%252Bof%252BNovel%252BPerfluorocarbon-Modulated%252B4-Anilinoquinazoline%252BAnalogues%26aulast%3DShi%26aufirst%3DHuiping%26date%3D2017%26date%3D2017%26volume%3D35%26issue%3D11%26spage%3D1693%26epage%3D1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jubo  Wang</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xiaqiu  Qiu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Libin  Wei</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 421-434. <a href="https://doi.org/10.1016/j.ejmech.2017.09.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bsynthesis%252Bof%252Bnovel%252BWogonin%252Bderivatives%252Bwith%252Bpotent%252Bantitumor%252Bactivity%252Bin%2525C2%2525A0vitro%26aulast%3DWang%26aufirst%3DJubo%26date%3D2017%26volume%3D140%26spage%3D421%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Xingsen  Wu</span>, <span class="hlFld-ContribAuthor ">Yanan  Dong</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>. </span><span class="cited-content_cbyCitation_article-title">2-Substituted 3,7,8-trimethylnaphtho[1,2- b ]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 616-629. <a href="https://doi.org/10.1016/j.ejmech.2017.06.028" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.028%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Substituted%252B3%25252C7%25252C8-trimethylnaphtho%25255B1%25252C2-%252Bb%252B%25255Dfuran-4%25252C5-diones%252Bas%252Bspecific%252BL-shaped%252BNQO1-mediated%252Bredox%252Bmodulators%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DZhang%26aufirst%3DXiaojin%26date%3D2017%26volume%3D138%26spage%3D616%26epage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Mologni</span>, <span class="hlFld-ContribAuthor ">Martina  Dalla Via</span>, <span class="hlFld-ContribAuthor ">Adriana  Chilin</span>, <span class="hlFld-ContribAuthor ">Manlio  Palumbo</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of
              wt
              RET and
              V804M
              RET Inhibitors: From Hit to Lead. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (16)
                                     , 1390-1398. <a href="https://doi.org/10.1002/cmdc.201700243" title="DOI URL">https://doi.org/10.1002/cmdc.201700243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700243%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiscovery%252Bof%252Bwt%252BRET%252Band%252BV804M%252BRET%252BInhibitors%25253A%252BFrom%252BHit%252Bto%252BLead%26aulast%3DMologni%26aufirst%3DLuca%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D16%26spage%3D1390%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Xingjun  Guo</span>, <span class="hlFld-ContribAuthor ">Chencheng  Xie</span>, <span class="hlFld-ContribAuthor ">Jianxin  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">KIF15 promotes pancreatic cancer proliferation via the MEK–ERK signalling pathway. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Cancer</span><span> <strong>2017,</strong> <em>117 </em>
                                    (2)
                                     , 245-255. <a href="https://doi.org/10.1038/bjc.2017.165" title="DOI URL">https://doi.org/10.1038/bjc.2017.165</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/bjc.2017.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fbjc.2017.165%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Cancer%26atitle%3DKIF15%252Bpromotes%252Bpancreatic%252Bcancer%252Bproliferation%252Bvia%252Bthe%252BMEK%2525E2%252580%252593ERK%252Bsignalling%252Bpathway%26aulast%3DWang%26aufirst%3DJie%26date%3D2017%26date%3D2017%26volume%3D117%26issue%3D2%26spage%3D245%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dennis  Plenker</span>, <span class="hlFld-ContribAuthor ">Maximilian  Riedel</span>, <span class="hlFld-ContribAuthor ">Johannes  Brägelmann</span>, <span class="hlFld-ContribAuthor ">Marcel A.  Dammert</span>, <span class="hlFld-ContribAuthor ">Rakhee  Chauhan</span>, <span class="hlFld-ContribAuthor ">Phillip P.  Knowles</span>, <span class="hlFld-ContribAuthor ">Carina  Lorenz</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Mike  Bührmann</span>, <span class="hlFld-ContribAuthor ">Oliver  Pagel</span>, <span class="hlFld-ContribAuthor ">Verena  Tischler</span>, <span class="hlFld-ContribAuthor ">Andreas H.  Scheel</span>, <span class="hlFld-ContribAuthor ">Daniel  Schütte</span>, <span class="hlFld-ContribAuthor ">Yanrui  Song</span>, <span class="hlFld-ContribAuthor ">Justina  Stark</span>, <span class="hlFld-ContribAuthor ">Florian  Mrugalla</span>, <span class="hlFld-ContribAuthor ">Yannic  Alber</span>, <span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Frauke  Leenders</span>, <span class="hlFld-ContribAuthor ">Johannes M.  Heuckmann</span>, <span class="hlFld-ContribAuthor ">Jürgen  Wolf</span>, <span class="hlFld-ContribAuthor ">Joachim  Diebold</span>, <span class="hlFld-ContribAuthor ">Georg  Pall</span>, <span class="hlFld-ContribAuthor ">Martin  Peifer</span>, <span class="hlFld-ContribAuthor ">Maarten  Aerts</span>, <span class="hlFld-ContribAuthor ">Kris  Gevaert</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Reinhard  Buettner</span>, <span class="hlFld-ContribAuthor ">Kevan M.  Shokat</span>, <span class="hlFld-ContribAuthor ">Neil Q.  McDonald</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Kast</span>, <span class="hlFld-ContribAuthor ">Oliver  Gautschi</span>, <span class="hlFld-ContribAuthor ">Roman K.  Thomas</span>, <span class="hlFld-ContribAuthor ">Martin L.  Sos</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. </span><span class="cited-content_cbyCitation_journal-name">Science Translational Medicine</span><span> <strong>2017,</strong> <em>9 </em>
                                    (394)
                                     , eaah6144. <a href="https://doi.org/10.1126/scitranslmed.aah6144" title="DOI URL">https://doi.org/10.1126/scitranslmed.aah6144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scitranslmed.aah6144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscitranslmed.aah6144%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Translational%2520Medicine%26atitle%3DDrugging%252Bthe%252Bcatalytically%252Binactive%252Bstate%252Bof%252BRET%252Bkinase%252Bin%252BRET-rearranged%252Btumors%26aulast%3DPlenker%26aufirst%3DDennis%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D394%26spage%3Deaah6144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter M.  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (2)
                                     , 314-367. <a href="https://doi.org/10.1002/med.21409" title="DOI URL">https://doi.org/10.1002/med.21409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21409%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DApproved%252Band%252BExperimental%252BSmall-Molecule%252BOncology%252BKinase%252BInhibitor%252BDrugs%25253A%252BA%252BMid-2016%252BOverview%26aulast%3DFischer%26aufirst%3DPeter%2BM.%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D2%26spage%3D314%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Mologni</span>, <span class="hlFld-ContribAuthor ">Carlo  Gambacorti-Passerini</span>, <span class="hlFld-ContribAuthor ">Peter  Goekjian</span>, <span class="hlFld-ContribAuthor ">Leonardo  Scapozza</span>. </span><span class="cited-content_cbyCitation_article-title">RET kinase inhibitors: a review of recent patents (2012–2015). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (1)
                                     , 91-99. <a href="https://doi.org/10.1080/13543776.2017.1238073" title="DOI URL">https://doi.org/10.1080/13543776.2017.1238073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1238073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1238073%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRET%252Bkinase%252Binhibitors%25253A%252Ba%252Breview%252Bof%252Brecent%252Bpatents%252B%2525282012%2525E2%252580%2525932015%252529%26aulast%3DMologni%26aufirst%3DLuca%26date%3D2017%26date%3D2016%26volume%3D27%26issue%3D1%26spage%3D91%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Vandetanib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 305-330. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00014-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00014-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00014-7%26sid%3Dliteratum%253Aachs%26atitle%3DVandetanib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D305%26epage%3D330%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 481-504. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00022-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00022-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00022-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00022-6%26sid%3Dliteratum%253Aachs%26atitle%3DPonatinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D481%26epage%3D504%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengbo  Song</span>, <span class="hlFld-ContribAuthor ">Xinmin  Yu</span>, <span class="hlFld-ContribAuthor ">Yiping  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2016,</strong> <em>101 </em>, 16-21. <a href="https://doi.org/10.1016/j.lungcan.2016.09.002" title="DOI URL">https://doi.org/10.1016/j.lungcan.2016.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2016.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2016.09.002%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DClinicopathologic%252Bcharacteristics%25252C%252Bgenetic%252Bvariability%252Band%252Btherapeutic%252Boptions%252Bof%252BRET%252Brearrangements%252Bpatients%252Bin%252Blung%252Badenocarcinoma%26aulast%3DSong%26aufirst%3DZhengbo%26date%3D2016%26volume%3D101%26spage%3D16%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Lin</span>, <span class="hlFld-ContribAuthor ">Shanshan  Wang</span>, <span class="hlFld-ContribAuthor ">Weiwei  Xie</span>, <span class="hlFld-ContribAuthor ">Rongliang  Zheng</span>, <span class="hlFld-ContribAuthor ">Yu  Gan</span>, <span class="hlFld-ContribAuthor ">Jianhua  Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (37)
                                     , 59236-59244. <a href="https://doi.org/10.18632/oncotarget.10985" title="DOI URL">https://doi.org/10.18632/oncotarget.10985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.10985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.10985%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DApatinib%252Binhibits%252Bcellular%252Binvasion%252Band%252Bmigration%252Bby%252Bfusion%252Bkinase%252BKIF5B-RET%252Bvia%252Bsuppressing%252BRET%25252FSrc%252Bsignaling%252Bpathway%26aulast%3DLin%26aufirst%3DChen%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D37%26spage%3D59236%26epage%3D59244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lois M.  Mulligan</span>. </span><span class="cited-content_cbyCitation_article-title">Progress and potential impact of RET kinase targeting in cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Proteomics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (7)
                                     , 631-633. <a href="https://doi.org/10.1080/14789450.2016.1205491" title="DOI URL">https://doi.org/10.1080/14789450.2016.1205491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14789450.2016.1205491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14789450.2016.1205491%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Proteomics%26atitle%3DProgress%252Band%252Bpotential%252Bimpact%252Bof%252BRET%252Bkinase%252Btargeting%252Bin%252Bcancer%26aulast%3DMulligan%26aufirst%3DLois%2BM.%26date%3D2016%26date%3D2016%26volume%3D13%26issue%3D7%26spage%3D631%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi-Sook  Lee</span>, <span class="hlFld-ContribAuthor ">Ryong Nam  Kim</span>, <span class="hlFld-ContribAuthor ">Hoseok  I</span>, <span class="hlFld-ContribAuthor ">Doo-Yi  Oh</span>, <span class="hlFld-ContribAuthor ">Ji-Young  Song</span>, <span class="hlFld-ContribAuthor ">Ka-Won  Noh</span>, <span class="hlFld-ContribAuthor ">Yu-Jin  Kim</span>, <span class="hlFld-ContribAuthor ">Jung Wook  Yang</span>, <span class="hlFld-ContribAuthor ">Maruja E.  Lira</span>, <span class="hlFld-ContribAuthor ">Chang Hun  Lee</span>, <span class="hlFld-ContribAuthor ">Min Ki  Lee</span>, <span class="hlFld-ContribAuthor ">Yeoung Dae  Kim</span>, <span class="hlFld-ContribAuthor ">Mao  Mao</span>, <span class="hlFld-ContribAuthor ">Joungho  Han</span>, <span class="hlFld-ContribAuthor ">Jhingook  Kim</span>, <span class="hlFld-ContribAuthor ">Yoon-La  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a novel partner gene,
              KIAA1217
              , fused to
              RET
              : Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (24)
                                     , 36101-36114. <a href="https://doi.org/10.18632/oncotarget.9137" title="DOI URL">https://doi.org/10.18632/oncotarget.9137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.9137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.9137%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DIdentification%252Bof%252Ba%252Bnovel%252Bpartner%252Bgene%25252C%252BKIAA1217%252B%25252C%252Bfused%252Bto%252BRET%252B%25253A%252BFunctional%252Bcharacterization%252Band%252Binhibitor%252Bsensitivity%252Bof%252Btwo%252Bisoforms%252Bin%252Blung%252Badenocarcinoma%26aulast%3DLee%26aufirst%3DMi-Sook%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D24%26spage%3D36101%26epage%3D36114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allan M.  Jordan</span>, <span class="hlFld-ContribAuthor ">Habiba  Begum</span>, <span class="hlFld-ContribAuthor ">Emma  Fairweather</span>, <span class="hlFld-ContribAuthor ">Samantha  Fritzl</span>, <span class="hlFld-ContribAuthor ">Kristin  Goldberg</span>, <span class="hlFld-ContribAuthor ">Gemma V.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Niall M.  Hamilton</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Lyons</span>, <span class="hlFld-ContribAuthor ">H. Nikki  March</span>, <span class="hlFld-ContribAuthor ">Rebecca  Newton</span>, <span class="hlFld-ContribAuthor ">Helen F.  Small</span>, <span class="hlFld-ContribAuthor ">Swamy  Vishwanath</span>, <span class="hlFld-ContribAuthor ">Ian D.  Waddell</span>, <span class="hlFld-ContribAuthor ">Bohdan  Waszkowycz</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Watson</span>, <span class="hlFld-ContribAuthor ">Donald J.  Ogilvie</span>. </span><span class="cited-content_cbyCitation_article-title">Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (11)
                                     , 2724-2729. <a href="https://doi.org/10.1016/j.bmcl.2016.03.100" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.03.100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.03.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.03.100%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAnilinoquinazoline%252Binhibitors%252Bof%252Bthe%252BRET%252Bkinase%252Bdomain%2525E2%252580%252594Elaboration%252Bof%252Bthe%252B7-position%26aulast%3DJordan%26aufirst%3DAllan%2BM.%26date%3D2016%26volume%3D26%26issue%3D11%26spage%3D2724%26epage%3D2729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nabin  Khanal</span>, <span class="hlFld-ContribAuthor ">Apar Kishor  Ganti</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging targeted therapies in non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2016,</strong> <em>16 </em>
                                    (2)
                                     , 177-187. <a href="https://doi.org/10.1586/14737140.2016.1126514" title="DOI URL">https://doi.org/10.1586/14737140.2016.1126514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1586/14737140.2016.1126514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1586%2F14737140.2016.1126514%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DEmerging%252Btargeted%252Btherapies%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DKhanal%26aufirst%3DNabin%26date%3D2016%26date%3D2016%26volume%3D16%26issue%3D2%26spage%3D177%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda J.  Watson</span>, <span class="hlFld-ContribAuthor ">Gemma V.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Samantha  Hitchin</span>, <span class="hlFld-ContribAuthor ">Habiba  Begum</span>, <span class="hlFld-ContribAuthor ">Stuart  Jones</span>, <span class="hlFld-ContribAuthor ">Allan  Jordan</span>, <span class="hlFld-ContribAuthor ">Sarah  Holt</span>, <span class="hlFld-ContribAuthor ">H. Nikki  March</span>, <span class="hlFld-ContribAuthor ">Rebecca  Newton</span>, <span class="hlFld-ContribAuthor ">Helen  Small</span>, <span class="hlFld-ContribAuthor ">Alex  Stowell</span>, <span class="hlFld-ContribAuthor ">Ian D.  Waddell</span>, <span class="hlFld-ContribAuthor ">Bohdan  Waszkowycz</span>, <span class="hlFld-ContribAuthor ">Donald J.  Ogilvie</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. </span><span class="cited-content_cbyCitation_journal-name">F1000Research</span><span> <strong>2016,</strong> <em>5 </em>, 1005. <a href="https://doi.org/10.12688/f1000research.8724.2" title="DOI URL">https://doi.org/10.12688/f1000research.8724.2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/f1000research.8724.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Ff1000research.8724.2%26sid%3Dliteratum%253Aachs%26jtitle%3DF1000Research%26atitle%3DIdentification%252Bof%252Bselective%252Binhibitors%252Bof%252BRET%252Band%252Bcomparison%252Bwith%252Bcurrent%252Bclinical%252Bcandidates%252Bthrough%252Bdevelopment%252Band%252Bvalidation%252Bof%252Ba%252Brobust%252Bscreening%252Bcascade%26aulast%3DWatson%26aufirst%3DAmanda%2BJ.%26date%3D2016%26date%3D2016%26volume%3D5%26spage%3D1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minsoo  Song</span>, <span class="hlFld-ContribAuthor ">Seong-Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Suk Kyoon  Yoon</span>. </span><span class="cited-content_cbyCitation_article-title">Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2015,</strong> <em>38 </em>
                                    (12)
                                     , 2120-2123. <a href="https://doi.org/10.1007/s12272-015-0660-1" title="DOI URL">https://doi.org/10.1007/s12272-015-0660-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-015-0660-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-015-0660-1%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DCabozantinib%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252BKIF5B-RET%252Bfusion.%252BAn%252Bexample%252Bof%252Bswift%252Brepositioning%26aulast%3DSong%26aufirst%3DMinsoo%26date%3D2015%26date%3D2015%26volume%3D38%26issue%3D12%26spage%3D2120%26epage%3D2123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Small-molecule TKIs for NSCLC approved by the U.S. FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic representations of wild-type KIF5B, RET proteins, and KIF5B-RET fusions in LADC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Small-molecule RET inhibitors under clinical development for NSCLC with KIF5B-RET rearrangements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ligand binding sites. Electron density maps around ZD6474 (A) and PP1 (B) show REFMAC-calculated electron density maps with 2<i>mF</i><sub>o</sub> −<i>DF</i><sub>c</sub> contoured at 1σ in green and <i>mF</i><sub>o</sub> – <i>DF</i><sub>c</sub> contoured at 3σ in blue and (in part A) contoured at 8σ in red. Parts C and D are Ligplot schematic diagrams of vandetanib and PP1 contacts with RET. Water molecules (W) are shown in cyan. Parts E–G show molecular surfaces of the ligand binding pockets in RET-KD-P, with the solvent side of the surface in white and the inside of the surface in blue-green. Ligands are shown in stick form, with carbon atoms in magenta for vandetanib (<i>E</i>), green for AMP (F), and brown for PP1 (G). The Val<sup>804</sup> side chain is highlighted in yellow. The pocket with access that is controlled by Val<sup>804</sup> is in the center of each diagram; a second apparent pocket (∗) in parts E and G is the result of the Phe<sup>735</sup> side chain being disordered in these two complexes. This research was originally published in  <cite>J. Biol. Chem.</cite> <span class="NLM_year">2006</span>, <em>281</em>, 33577–33587.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> ©American Society for Biochemistry and Molecular Biology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mapping of disease-linked mutations in the RET kinase structure. Activating mutation sites in RET-KD identified in MTC, MEN2A, and MEN2B. Carbon atoms of the side chains are colored magenta for M918T, the predominant MEN2B mutant; pink for E768D/A919P; white for V804M/Y806C, two paired mutations where there is synergy; and cyan for L790F, Y791F, S891A, and R844L. The backbone schematic of RET-KD is shown in green, with the link to the N-terminal helix and the kinase insert domain indicated by dashed lines. The side chains of the wild-type RET-KD are shown, and the bound nucleotide is shown in stick form. This research was originally published in  <cite>J. Biol. Chem.</cite> <span class="NLM_year">2006</span>, <em>281</em>, 33577–33587.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> ©American Society for Biochemistry and Molecular Biology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/medium/jm-2014-01464c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding modes of small-molecule RET kinase inhibitors. Kinase inhibitor–protein interactions are depicted in the chemical structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jm501464c/20150508/images/large/jm-2014-01464c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501464c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>World Cancer Research Fund International. <a href="http://www.wcrf.org/index.php" class="extLink">http://www.wcrf.org/index.php</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Cancer+Research+Fund+International.+http%3A%2F%2Fwww.wcrf.org%2Findex.php+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span>National Cancer Institute. Surveillance, Epidemiology, and End Results Program. <a href="http://seer.cancer.gov" class="extLink">http://seer.cancer.gov</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Cancer+Institute.+Surveillance%2C+Epidemiology%2C+and+End+Results+Program.+http%3A%2F%2Fseer.cancer.gov+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>American Cancer Society. Cancer Facts and Figures 2014. <a href="http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/" class="extLink">http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=American+Cancer+Society.+Cancer+Facts+and+Figures+2014.+http%3A%2F%2Fwww.cancer.org%2Fresearch%2Fcancerfactsstatistics%2Fcancerfactsfigures2014%2F+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Minuti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incecco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span> </span><span class="NLM_article-title">Targeted therapy for NSCLC with driver mutations</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1517%2F14712598.2013.827657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23930754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVektrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1401-1412&author=G.+Minutiauthor=A.+D%E2%80%99Inceccoauthor=F.+Cappuzzo&title=Targeted+therapy+for+NSCLC+with+driver+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for NSCLC with driver mutations</span></div><div class="casAuthors">Minuti, Gabriele; D'Incecco, Armida; Cappuzzo, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1401-1412</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Activating mutations of the epidermal growth factor receptor (EGFR) gene and rearrangement of anaplastic lymphoma kinase (ALK) gene best illustrate the therapeutic relevance of mol. characterization in non-small cell lung cancer (NSCLC) patients.  Several genetic aberrations with a potential prognostic or predictive role have been identified, mainly in adenocarcinoma subtype, including ROS1, RET, MET, HER2, BRAF and KRAS.  More recently oncogenic drivers, such as DDR2, FGFR1 and PI3KCA, have been characterized in squamous cell lung carcinoma (SCC) and target agents are currently under evaluation.  The aim of this review is to summarize the growing scenario of new targetable oncogenes in NSCLC.  Areas covered: For this review article all published data on NSCLC genomic alterations, including the techniques employed for oncogenic drivers identification, the prevalence of each one in lung cancer subtypes, the preclin. data corroborating their role in tumorigenesis and the potential biol. tailored agents tested and under evaluation were collected and analyzed using PubMed.  Expert opinion: Oncogenic products represent reliable targets for drug therapy and the expanding knowledge of mol. pathways involved in lung tumorigenesis is resulting in a dramatic change of treatment strategies leading to an improvement in disease and symptom control, extending life duration and improving quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodEsO_1XneLVg90H21EOLACvtfcHk0ljJrRtW5N7Ypw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVektrbM&md5=d5ef58a3a80f9bb5c49b4c7d8567a949</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14712598.2013.827657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2013.827657%26sid%3Dliteratum%253Aachs%26aulast%3DMinuti%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Incecco%26aufirst%3DA.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DTargeted%2520therapy%2520for%2520NSCLC%2520with%2520driver%2520mutations%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D1401%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Forde, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, D. S.</span><span> </span><span class="NLM_article-title">Targeted therapy for non-small-cell lung cancer: past, present and future</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">758</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1586%2Fera.13.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23773106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFKiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=745-758&author=P.+M.+Fordeauthor=D.+S.+Ettinger&title=Targeted+therapy+for+non-small-cell+lung+cancer%3A+past%2C+present+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for non-small-cell lung cancer: past, present and future</span></div><div class="casAuthors">Forde, Patrick M.; Ettinger, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-758</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histol. subtype as an important factor in guiding treatment and the development of targeted agents for mol. subgroups harboring crit. mutations that spur on cancer growth.  In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK.  This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz1_lFCYvFNbVg90H21EOLACvtfcHk0ljJrRtW5N7Ypw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFKiur8%253D&md5=fdd2c66ec4e6d506a28d0f57c6a4d012</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1586%2Fera.13.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.13.47%26sid%3Dliteratum%253Aachs%26aulast%3DForde%26aufirst%3DP.%2BM.%26aulast%3DEttinger%26aufirst%3DD.%2BS.%26atitle%3DTargeted%2520therapy%2520for%2520non-small-cell%2520lung%2520cancer%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2013%26volume%3D13%26spage%3D745%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><div class="note"><p class="first last">A review on irreversible kinase inhibitors.</p></div><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0liJAn78bOmdAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span>U.S. Food and Drug Administration. News & Events (released Apr 29,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span><a href="http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm" class="extLink">http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+and+Drug+Administration.+News+%26+Events+%28released+Apr+29%2C+2014%29+http%3A%2F%2Fwww.fda.gov%2Fnewsevents%2Fnewsroom%2Fpressannouncements%2Fucm395299.htm+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, K. E.</span><span> </span><span class="NLM_article-title">Chipping away at the lung cancer genome</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22395697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1yhtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=349-351&author=W.+Paoauthor=K.+E.+Hutchinson&title=Chipping+away+at+the+lung+cancer+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Chipping away at the lung cancer genome</span></div><div class="casAuthors">Pao, William; Hutchinson, Katherine E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-351</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are now std. treatment for patients with lung cancer whose tumors harbor specific mutant kinases.  Four recent studies, including 3 in this issue (pages 375-384), have identified new fusion proteins involving another receptor tyrosine kinase that may potentially be responsive to existing targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMVnaQExHaYrVg90H21EOLACvtfcHk0liJAn78bOmdAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1yhtrs%253D&md5=8ab9f744a70dc422ebad03650ce22367</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnm.2697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2697%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DHutchinson%26aufirst%3DK.%2BE.%26atitle%3DChipping%2520away%2520at%2520the%2520lung%2520cancer%2520genome%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D349%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kohno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totoki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiramoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nammo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada1, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwakawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogiwara1, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oike, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaug, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiku, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekine, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, T.</span><span> </span><span class="NLM_article-title">KIF5B-RET fusion in lung adenocarcinoma</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22327624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=375&author=T.+Kohnoauthor=H.+Ichikawaauthor=Y.+Totokiauthor=K.+Yasudaauthor=M.+Hiramotoauthor=T.+Nammoauthor=H.+Sakamotoauthor=K.+Tsutaauthor=K.+Furutaauthor=Y.+Shimada1author=R.+Iwakawaauthor=H.+Ogiwara1author=T.+Oikeauthor=M.+Enariauthor=A.+J.+Schetterauthor=H.+Okayamaauthor=A.+Haugenauthor=V.+Skaugauthor=S.+Chikuauthor=I.+Yamanakaauthor=Y.+Araiauthor=S.-i.+Watanabeauthor=I.+Sekineauthor=S.+Ogawaauthor=C.+C.+Harrisauthor=H.+Tsudaauthor=T.+Yoshidaauthor=J.+Yokotaauthor=T.+Shibata&title=KIF5B-RET+fusion+in+lung+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">KIF5B-RET fusions in lung adenocarcinoma</span></div><div class="casAuthors">Kohno, Takashi; Ichikawa, Hitoshi; Totoki, Yasushi; Yasuda, Kazuki; Hiramoto, Masaki; Nammo, Takao; Sakamoto, Hiromi; Tsuta, Koji; Furuta, Koh; Shimada, Yoko; Iwakawa, Reika; Ogiwara, Hideaki; Oike, Takahiro; Enari, Masato; Schetter, Aaron J.; Okayama, Hirokazu; Haugen, Aage; Skaug, Vidar; Chiku, Suenori; Yamanaka, Itaru; Arai, Yasuhito; Watanabe, Shun-ichi; Sekine, Ikuo; Ogawa, Seishi; Harris, Curtis C.; Tsuda, Hitoshi; Yoshida, Teruhiko; Yokota, Jun; Shibata, Tatsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-377</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing.  The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQqNYV3xGfbVg90H21EOLACvtfcHk0ljAyObnqRLvNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D&md5=301f964ad413e020aba11122dff13054</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnm.2644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2644%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DTotoki%26aufirst%3DY.%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DHiramoto%26aufirst%3DM.%26aulast%3DNammo%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DFuruta%26aufirst%3DK.%26aulast%3DShimada1%26aufirst%3DY.%26aulast%3DIwakawa%26aufirst%3DR.%26aulast%3DOgiwara1%26aufirst%3DH.%26aulast%3DOike%26aufirst%3DT.%26aulast%3DEnari%26aufirst%3DM.%26aulast%3DSchetter%26aufirst%3DA.%2BJ.%26aulast%3DOkayama%26aufirst%3DH.%26aulast%3DHaugen%26aufirst%3DA.%26aulast%3DSkaug%26aufirst%3DV.%26aulast%3DChiku%26aufirst%3DS.%26aulast%3DYamanaka%26aufirst%3DI.%26aulast%3DArai%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DS.-i.%26aulast%3DSekine%26aufirst%3DI.%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DYokota%26aufirst%3DJ.%26aulast%3DShibata%26aufirst%3DT.%26atitle%3DKIF5B-RET%2520fusion%2520in%2520lung%2520adenocarcinoma%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamanaka, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninomiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okumura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span> </span><span class="NLM_article-title">RET, ROS1 and ALK fusion in lung cancer</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22327623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=378-381&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=R.+Suzukiauthor=S.+Sakataauthor=S.+Hatanoauthor=R.+Asakaauthor=W.+Hamanakaauthor=H.+Ninomiyaauthor=H.+Ueharaauthor=Y.+L.+Choiauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=H.+Manoauthor=Y.+Ishikawa&title=RET%2C+ROS1+and+ALK+fusion+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RET, ROS1 and ALK fusions in lung cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Suzuki, Ritsuro; Sakata, Seiji; Hatano, Satoko; Asaka, Reimi; Hamanaka, Wakako; Ninomiya, Hironori; Uehara, Hirofumi; Lim Choi, Young; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Mano, Hiroyuki; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">378-381</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Through an integrated mol.- and histopathol.-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-pos. and 13 ROS1-fusion-pos. adenocarcinomas, including for unidentified fusion partners for ROS1.  In addn., we discovered previously unidentified kinase fusions that may be promising for mol.-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain contg. 6 (CCDC6)-RET, in 14 adenocarcinomas.  A multivariate anal. of 1,116 adenocarcinomas contg. these 71 kinase-fusion-pos. adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathol. stage and neg. kinase-fusion status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJr0BIAnHWLVg90H21EOLACvtfcHk0ljAyObnqRLvNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D&md5=986c7eba0992b29950756e129a395d60</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm.2658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2658%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSakata%26aufirst%3DS.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DHamanaka%26aufirst%3DW.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DRET%252C%2520ROS1%2520and%2520ALK%2520fusion%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D378%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelensky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarosz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donahue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frampton, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juhn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell1, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwirko, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peretz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nechushtan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soussan-Gutman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span> </span><span class="NLM_article-title">Identification of new <i>ALK</i> and <i>RET</i> gene fusions from colorectal and lung cancer biopsies</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">382</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnm.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22327622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=382-384&author=D.+Lipsonauthor=M.+Capellettiauthor=R.+Yelenskyauthor=G.+Ottoauthor=A.+Parkerauthor=M.+Jaroszauthor=J.+A.+Curranauthor=S.+Balasubramanianauthor=T.+Bloomauthor=K.+W.+Brennanauthor=A.+Donahueauthor=S.+R.+Downingauthor=G.+M.+Framptonauthor=L.+Garciaauthor=F.+Juhnauthor=K.+C.+Mitchell1author=E.+Whiteauthor=J.+Whiteauthor=Z.+Zwirkoauthor=T.+Peretzauthor=H.+Nechushtanauthor=L.+Soussan-Gutmanauthor=J.+Kimauthor=H.+Sasakiauthor=H.+R.+Kimauthor=S.-i.+Parkauthor=D.+Ercanauthor=C.+E.+Sheehanauthor=J.+S.+Rossauthor=M.+T.+Croninauthor=P.+A.+J%C3%A4nneauthor=P.+J.+Stephens&title=Identification+of+new+ALK+and+RET+gene+fusions+from+colorectal+and+lung+cancer+biopsies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies</span></div><div class="casAuthors">Lipson, Doron; Capelletti, Marzia; Yelensky, Roman; Otto, Geoff; Parker, Alex; Jarosz, Mirna; Curran, John A.; Balasubramanian, Sohail; Bloom, Troy; Brennan, Kristina W.; Donahue, Amy; Downing, Sean R.; Frampton, Garrett M.; Garcia, Lazaro; Juhn, Frank; Mitchell, Kathy C.; White, Emily; White, Jared; Zwirko, Zac; Peretz, Tamar; Nechushtan, Hovav; Soussan-Gutman, Lior; Kim, Jhingook; Sasaki, Hidefumi; Kim, Hyeong Ryul; Park, Seung-il; Ercan, Dalia; Sheehan, Christine E.; Ross, Jeffrey S.; Cronin, Maureen T.; Jaenne, Pasi A.; Stephens, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-384</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clin. relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma.  Further screening of 561 lung adenocarcinomas identified 11 addnl. tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%).  Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9dSer699HbVg90H21EOLACvtfcHk0lhpd2yIRF6jdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D&md5=9ab47602d1e1ed547cb852a34d29e5bb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2673%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DCurran%26aufirst%3DJ.%2BA.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DBloom%26aufirst%3DT.%26aulast%3DBrennan%26aufirst%3DK.%2BW.%26aulast%3DDonahue%26aufirst%3DA.%26aulast%3DDowning%26aufirst%3DS.%2BR.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DJuhn%26aufirst%3DF.%26aulast%3DMitchell1%26aufirst%3DK.%2BC.%26aulast%3DWhite%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DZwirko%26aufirst%3DZ.%26aulast%3DPeretz%26aufirst%3DT.%26aulast%3DNechushtan%26aufirst%3DH.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPark%26aufirst%3DS.-i.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DSheehan%26aufirst%3DC.%2BE.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26atitle%3DIdentification%2520of%2520new%2520ALK%2520and%2520RET%2520gene%2520fusions%2520from%2520colorectal%2520and%2520lung%2520cancer%2520biopsies%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D382%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Ju, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleazard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, J.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.-S.</span><span> </span><span class="NLM_article-title">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</span> <span class="citation_source-journal">Genome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1101%2Fgr.133645.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22194472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2lsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=436-445&author=Y.+S.+Juauthor=W.-C.+Leeauthor=J.-Y.+Shinauthor=S.+Leeauthor=T.+Bleazardauthor=J.-K.+Wonauthor=Y.+T.+Kimauthor=J.-I.+Kimauthor=J.-H.+Kangauthor=J.-S.+Seo&title=A+transforming+KIF5B+and+RET+gene+fusion+in+lung+adenocarcinoma+revealed+from+whole-genome+and+transcriptome+sequencing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</span></div><div class="casAuthors">Ju, Young Seok; Lee, Won-Chul; Shin, Jong-Yeon; Lee, Seungbok; Bleazard, Thomas; Won, Jae-Kyung; Kim, Young Tae; Kim, Jong-Il; Kang, Jin-Hyoung; Seo, Jeong-Sun</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">436-445</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The identification of the mol. events that drive cancer transformation is essential to the development of targeted agents that improve the clin. outcome of lung cancer.  Many studies have reported genomic driver mutations in non-small-cell lung cancers (NSCLCs) over the past decade; however, the mol. pathogenesis of >40% of NSCLCs is still unknown.  To identify new mol. targets in NSCLCs, we performed the combined anal. of massively parallel whole-genome and transcriptome sequencing for cancer and paired normal tissue of a 33-yr-old lung adenocarcinoma patient, who is a never-smoker and has no familial cancer history.  The cancer showed no known driver mutation in EGFR or KRAS and no EML4-ALK fusion.  Here we report a novel fusion gene between KIF5B and the RET proto-oncogene caused by a pericentric inversion of 10p11.22-q11.21.  This fusion gene overexpresses chimeric RET receptor tyrosine kinase, which could spontaneously induce cellular transformation.  We identified the KIF5B-RET fusion in two more cases out of 20 primary lung adenocarcinomas in the replication study.  Our data demonstrate that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggest the chimeric oncogene as a promising mol. target for the personalized diagnosis and treatment of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBEXolltRgLVg90H21EOLACvtfcHk0lhpd2yIRF6jdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2lsLk%253D&md5=a95455b1a7d548e5116be4f5107fd9f4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1101%2Fgr.133645.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.133645.111%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DY.%2BS.%26aulast%3DLee%26aufirst%3DW.-C.%26aulast%3DShin%26aufirst%3DJ.-Y.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBleazard%26aufirst%3DT.%26aulast%3DWon%26aufirst%3DJ.-K.%26aulast%3DKim%26aufirst%3DY.%2BT.%26aulast%3DKim%26aufirst%3DJ.-I.%26aulast%3DKang%26aufirst%3DJ.-H.%26aulast%3DSeo%26aufirst%3DJ.-S.%26atitle%3DA%2520transforming%2520KIF5B%2520and%2520RET%2520gene%2520fusion%2520in%2520lung%2520adenocarcinoma%2520revealed%2520from%2520whole-genome%2520and%2520transcriptome%2520sequencing%26jtitle%3DGenome%2520Res.%26date%3D2012%26volume%3D22%26spage%3D436%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span> </span><span class="NLM_article-title">RET revisited: expanding the oncogenic portfolio</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnrc3680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=24561444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=173-186&author=L.+M.+Mulligan&title=RET+revisited%3A+expanding+the+oncogenic+portfolio"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">RET revisited: expanding the oncogenic portfolio</span></div><div class="casAuthors">Mulligan, Lois M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-186</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RET receptor tyrosine kinase is crucial for normal development but also contributes to pathologies that reflect both the loss and the gain of RET function.  Activation of RET occurs via oncogenic mutations in familial and sporadic cancers - most notably, those of the thyroid and the lung.  RET has also recently been implicated in the progression of breast and pancreatic tumors, among others, which makes it an attractive target for small-mol. kinase inhibitors as therapeutics.  However, the complex roles of RET in homeostasis and survival of neural lineages and in tumor-assocd. inflammation might also suggest potential long-term pitfalls of broadly targeting RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohwDQSALnEwbVg90H21EOLACvtfcHk0lhpd2yIRF6jdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D&md5=665dae74c8f7a1df0e413ca15ca86440</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc3680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3680%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DRET%2520revisited%253A%2520expanding%2520the%2520oncogenic%2520portfolio%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D173%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span> </span><span class="NLM_article-title">Minireview: RET: Normal and abnormal functions</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">5448</span><span class="NLM_x">–</span> <span class="NLM_lpage">5451</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2004&pages=5448-5451&author=M.+Santoroauthor=R.+M.+Melilloauthor=F.+Carlomagnoauthor=G.+Vecchioauthor=A.+Fusco&title=Minireview%3A+RET%3A+Normal+and+abnormal+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DMelillo%26aufirst%3DR.%2BM.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26atitle%3DMinireview%253A%2520RET%253A%2520Normal%2520and%2520abnormal%2520functions%26jtitle%3DEndocrinology%26date%3D2004%26volume%3D145%26spage%3D5448%26epage%3D5451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span>Hematology/Oncology (Cancer) Approvals & Safety Notifications. <a href="http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm" class="extLink">http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hematology%2FOncology+%28Cancer%29+Approvals+%26+Safety+Notifications.+http%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm279174.htm+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span>Targeted Cancer Therapies. <a href="http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted" class="extLink">http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Targeted+Cancer+Therapies.+http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Ffactsheet%2FTherapy%2Ftargeted+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Development of RET kinase inhibitors for targeted cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.2174%2F092986711794088308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=21110809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVWrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=162-175&author=L.+Mologni&title=Development+of+RET+kinase+inhibitors+for+targeted+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of RET kinase inhibitors for targeted cancer therapy</span></div><div class="casAuthors">Mologni, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-175</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  RET (Rearranged during Transfection) is a transmembrane tyrosine kinase expressed in central and peripheral nervous system and neural crest-derived cells and acts as a co-receptor of GDNF family neurotrophic factor in complex with GRFα family proteins.  RET protein comprises an extracellular portion with four cadherine-like domains and a cysteine-rich region important for intermol. interactions; a hydrophobic transmembrane domain; an intracellular part comprising the juxtamembrane domain with regulatory function and the catalytic domain that phosphorylates the tyrosine residues of substrates.  RET is involved in the development of enteric nervous system and renal organogenesis during embryonic life.  Mutations of RET are assocd. to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer.  Activating point mutations in the cystein-rich or the kinase domain of RET cause multiple endocrine neoplasia type 2 (MEN2), a group of familial cancer syndromes characterized by medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia and ganglioneuromatosis of the gastroenteric mucosa.  Rearranged forms of RET (termed RET/PTC) are detected in the majority of papillary thyroid carcinomas (PTC).  At present, the therapeutic treatment available for these pathologies is the total or partial surgical removal of thyroid, assocd. with radio-iodine therapy or chemotherapy: despite widespread use of multimodality treatment, survival rates have not improved much in the past few decades, which suggests that new treatment options should be explored.  Several small-mol. inhibitors of RET kinase activity have been described in the last decade, some of which are currently undergoing clin. evaluation.  Here, I review the large preclin. effort to the development of specific RET inhibitors, including medicinal chem. analyses that may help refine potency and selectivity of future RET-targeted inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7NbIf0vPkuLVg90H21EOLACvtfcHk0liUGcVSR9JoYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVWrt70%253D&md5=c67b95973706091ef5bd7d376a6bc090</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F092986711794088308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794088308%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520RET%2520kinase%2520inhibitors%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D162%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Matsui, J.; Minoshima, Y.; Tsuruoka, A.; Funahashi, Y.</span><span> </span><span class="NLM_article-title">Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition</span>.  <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">8, Suppl. 1</span>); Proceedings of the 101st Annual Meeting of AACR, Washington, DC, Apr 17–21, 2010; Abstract 3614.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&issue=8%2C+Suppl.+1&author=J.+Matsui&author=Y.+Minoshima&author=A.+Tsuruoka&author=Y.+Funahashi&title=Multi-targeted+kinase+inhibitor+E7080+showed+anti-tumor+activity+against+medullary+thyroid+carcinoma+and+squamous+thyroid+carcinoma+cell+line+based+on+RET+and+VEGFR2+tyrosine+kinase+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26atitle%3DMulti-targeted%2520kinase%2520inhibitor%2520E7080%2520showed%2520anti-tumor%2520activity%2520against%2520medullary%2520thyroid%2520carcinoma%2520and%2520squamous%2520thyroid%2520carcinoma%2520cell%2520line%2520based%2520on%2520RET%2520and%2520VEGFR2%2520tyrosine%2520kinase%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3D8%252C%2520Suppl.%25201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Schlumberger, M.; Tahara, M.; Wirth, L. J.; Robinson, B.; Brose, M. S.; Elisei, R.; Dutcus, C. E.; de las Heras, B.; Zhu, J.; Habra, M. A.; Newbold, K.; Shah, M. H.; Hoff, A. O.; Gianoukakis, A. G.; Kiyota, N.; Taylor, M. H.; Kim, S.-B.; Krzyzanowska, M. K.; Sherman, S. I.</span><span> </span><span class="NLM_article-title">A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup>I-refractory differentiated thyroid cancer (SELECT)</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span>; ASCO Annual Meeting Abstracts, No. 15_suppl (May 20 Supplement), 2014, LBA6008.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&author=M.+Schlumberger&author=M.+Tahara&author=L.+J.+Wirth&author=B.+Robinson&author=M.+S.+Brose&author=R.+Elisei&author=C.+E.+Dutcus&author=B.+de+las+Heras&author=J.+Zhu&author=M.+A.+Habra&author=K.+Newbold&author=M.+H.+Shah&author=A.+O.+Hoff&author=A.+G.+Gianoukakis&author=N.+Kiyota&author=M.+H.+Taylor&author=S.-B.+Kim&author=M.+K.+Krzyzanowska&author=S.+I.+Sherman&title=A+phase+3%2C+multicenter%2C+double-blind%2C+placebo-controlled+trial+of+lenvatinib+%28E7080%29+in+patients+with+131I-refractory+differentiated+thyroid+cancer+%28SELECT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchlumberger%26aufirst%3DM.%26atitle%3DA%2520phase%25203%252C%2520multicenter%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520lenvatinib%2520%2528E7080%2529%2520in%2520patients%2520with%2520131I-refractory%2520differentiated%2520thyroid%2520cancer%2520%2528SELECT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugi, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span> </span><span class="NLM_article-title">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.canlet.2013.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23856031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=97-103&author=K.+Okamotoauthor=K.+Kodamaauthor=K.+Takaseauthor=N.+H.+Sugiauthor=Y.+Yamamotoauthor=M.+Iwataauthor=A.+Tsuruoka&title=Antitumor+activities+of+the+targeted+multi-tyrosine+kinase+inhibitor+lenvatinib+%28E7080%29+against+RET+gene+fusion-driven+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span></div><div class="casAuthors">Okamoto, Kiyoshi; Kodama, Kotaro; Takase, Kazuma; Sugi, Naoko Hata; Yamamoto, Yuji; Iwata, Masao; Tsuruoka, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-103</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas.  Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clin. trials.  Here we evaluated lenvatinib in RET gene fusion-driven preclin. models.  In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET.  Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells.  These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr151nVk6WXn7Vg90H21EOLACvtfcHk0liUGcVSR9JoYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M&md5=e2399184aae74ae2c4b18997a6b7273b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKodama%26aufirst%3DK.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DSugi%26aufirst%3DN.%2BH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DTsuruoka%26aufirst%3DA.%26atitle%3DAntitumor%2520activities%2520of%2520the%2520targeted%2520multi-tyrosine%2520kinase%2520inhibitor%2520lenvatinib%2520%2528E7080%2529%2520against%2520RET%2520gene%2520fusion-driven%2520tumor%2520models%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D97%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitagliano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7284</span><span class="NLM_x">–</span> <span class="NLM_lpage">7290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=7284-7290&author=F.+Carlomagnoauthor=D.+Vitaglianoauthor=T.+Guidaauthor=F.+Ciardielloauthor=G.+Tortoraauthor=G.+Vecchioauthor=A.+J.+Ryanauthor=G.+Fontaniniauthor=A.+Fuscoauthor=M.+Santoro&title=ZD6474%2C+an+orally+available+inhibitor+of+KDR+tyrosine+kinase+activity%2C+efficiently+blocks+oncogenic+RET+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DFontanini%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DZD6474%252C%2520an%2520orally%2520available%2520inhibitor%2520of%2520KDR%2520tyrosine%2520kinase%2520activity%252C%2520efficiently%2520blocks%2520oncogenic%2520RET%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D7284%26epage%3D7290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjær, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibáñez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kj%C3%A6rauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0liTKYLf-U7_7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKj%25C3%25A6r%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Gautschi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebold, J.</span><span> </span><span class="NLM_article-title">A patient with lung adenocarcinoma and RET fusion treated with vandetanib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e43</span><span class="NLM_x">–</span> <span class="NLM_lpage">e44</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e43-e44&author=O.+Gautschiauthor=T.+Zanderauthor=F.+A.+Kellerauthor=K.+Strobelauthor=A.+Hirschmannauthor=S.+Aebiauthor=J.+Diebold&title=A+patient+with+lung+adenocarcinoma+and+RET+fusion+treated+with+vandetanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGautschi%26aufirst%3DO.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DKeller%26aufirst%3DF.%2BA.%26aulast%3DStrobel%26aufirst%3DK.%26aulast%3DHirschmann%26aufirst%3DA.%26aulast%3DAebi%26aufirst%3DS.%26aulast%3DDiebold%26aufirst%3DJ.%26atitle%3DA%2520patient%2520with%2520lung%2520adenocarcinoma%2520and%2520RET%2520fusion%2520treated%2520with%2520vandetanib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3De43%26epage%3De44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rha, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kweon, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shong, M.</span><span> </span><span class="NLM_article-title">An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">4070</span><span class="NLM_x">–</span> <span class="NLM_lpage">4076</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1210%2Fjc.2005-2845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=16849418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSjtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=4070-4076&author=D.+W.+Kimauthor=Y.+S.+Joauthor=H.+S.+Jungauthor=H.+K.+Chungauthor=J.+H.+Songauthor=K.+C.+Parkauthor=S.+H.+Parkauthor=J.+H.+Hwangauthor=S.+Y.+Rhaauthor=G.+R.+Kweonauthor=S.+J.+Leeauthor=K.+W.+Joauthor=M.+Shong&title=An+orally+administered+multitarget+tyrosine+kinase+inhibitor%2C+SU11248%2C+is+a+novel+potent+inhibitor+of+thyroid+oncogenic+RET%2Fpapillary+thyroid+cancer+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/Papillary thyroid cancer kinases</span></div><div class="casAuthors">Kim, Dong Wook; Jo, Young Suk; Jung, Hye Sook; Chung, Hyo Kyun; Song, Jung Hun; Park, Ki Cheol; Park, Su Hyeon; Hwang, Jung Hwan; Rha, So Young; Kweon, Gi Ryang; Lee, Su-Jae; Jo, Ki-Won; Shong, Minho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4070-4076</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Context: The oncogenic RET/PTC tyrosine kinase causes papillary thyroid cancer (PTC).  The use of inhibitors specific for RET/PTC may be useful for targeted therapy of PTC.  Objective: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC.  Design: SU11248, SU5416, and SU6668 were synthesized, and their inhibitory potencies were evaluated using an in vitro RET/PTC kinase assay.  The inhibitory effects of the compds. on RET/PTC were evaluated by quantifying the autophosphorylation of RET/PTC, signal transducer and activator of transcription (STAT)-3 activation, and the morphol. reversal of RET/PTC-transformed cells.  Results: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC50 of approx. 944 nM for SU5416, 562 nM for SU6668, and 224 nM for SU11248.  Thus, SU11248 effectively inhibits the kinase activity of RET/PTC3.  RET/PTC-mediated Y705 phosphorylation of STAT3 was inhibited by addn. of SU11248, and the inhibitory effects of SU11248 on the tyrosine phosphorylation and transcriptional activation of STAT3 were very closely correlated with decreased autophosphorylation of RET/PTC.  SU11248 caused a complete morphol. reversion of transformed NIH-RET/PTC3 cells and inhibited the growth of TPC-1 cells that have an endogenous RET/PTC1.  Conclusion: SU11248 is a highly effective tyrosine kinase inhibitor of the RET/PTC oncogenic kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbInzSrkRMBbVg90H21EOLACvtfcHk0liTKYLf-U7_7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSjtbrN&md5=05214e9ce472b7c562d53f4d95a39cb0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1210%2Fjc.2005-2845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2005-2845%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DJo%26aufirst%3DY.%2BS.%26aulast%3DJung%26aufirst%3DH.%2BS.%26aulast%3DChung%26aufirst%3DH.%2BK.%26aulast%3DSong%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DK.%2BC.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BH.%26aulast%3DRha%26aufirst%3DS.%2BY.%26aulast%3DKweon%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DJo%26aufirst%3DK.%2BW.%26aulast%3DShong%26aufirst%3DM.%26atitle%3DAn%2520orally%2520administered%2520multitarget%2520tyrosine%2520kinase%2520inhibitor%252C%2520SU11248%252C%2520is%2520a%2520novel%2520potent%2520inhibitor%2520of%2520thyroid%2520oncogenic%2520RET%252Fpapillary%2520thyroid%2520cancer%2520kinases%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2006%26volume%3D91%26spage%3D4070%26epage%3D4076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S.</span><span> </span><span class="NLM_article-title">An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline</span> <span class="citation_source-journal">ASCO Meet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">5508</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=5508&author=P.+Schoffskiauthor=R.+Eliseiauthor=S.+Muller&title=An+international%2C+double-blind%2C+randomized%2C+placebo-controlled+phase+III+trial+%28EXAM%29+of+cabozantinib+%28XL184%29+in+medullary+thyroid+carcinoma+%28MTC%29+patients+with+documented+RECIST+progression+at+baseline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DS.%26atitle%3DAn%2520international%252C%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520phase%2520III%2520trial%2520%2528EXAM%2529%2520of%2520cabozantinib%2520%2528XL184%2529%2520in%2520medullary%2520thyroid%2520carcinoma%2520%2528MTC%2529%2520patients%2520with%2520documented%2520RECIST%2520progression%2520at%2520baseline%26jtitle%3DASCO%2520Meet.%26date%3D2012%26volume%3D34%26spage%3D5508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><div class="note"><p class="first last">The first paper to show clinical activity of a RET inhibitor in patients with <i>RET</i>-rearranged NSCLC, validating RET as a molecular target in lung cancer:</p></div><span class="NLM_contrib-group">Drilon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasanovic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suehara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizvi, N.</span><span> </span><span class="NLM_article-title">Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">630</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=630-635&author=A.+Drilonauthor=L.+Wangauthor=A.+Hasanovicauthor=Y.+Sueharaauthor=D.+Lipsonauthor=P.+Stephensauthor=J.+Rossauthor=V.+Millerauthor=M.+Ginsbergauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=N.+Rizvi&title=Response+to+cabozantinib+in+patients+with+RET+fusion-positive+lung+adenocarcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHasanovic%26aufirst%3DA.%26aulast%3DSuehara%26aufirst%3DY.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DGinsberg%26aufirst%3DM.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRizvi%26aufirst%3DN.%26atitle%3DResponse%2520to%2520cabozantinib%2520in%2520patients%2520with%2520RET%2520fusion-positive%2520lung%2520adenocarcinomas%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D630%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">De Falco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonocore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torregrossa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">E811</span><span class="NLM_x">–</span> <span class="NLM_lpage">E819</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=E811-E819&author=V.+De+Falcoauthor=P.+Buonocoreauthor=M.+Muthuauthor=L.+Torregrossaauthor=F.+Basoloauthor=M.+Billaudauthor=J.+M.+Gozgitauthor=F.+Carlomagnoauthor=M.+Santoro&title=Ponatinib+%28AP24534%29+is+a+novel+potent+inhibitor+of+oncogenic+RET+mutants+associated+with+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DBuonocore%26aufirst%3DP.%26aulast%3DMuthu%26aufirst%3DM.%26aulast%3DTorregrossa%26aufirst%3DL.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DPonatinib%2520%2528AP24534%2529%2520is%2520a%2520novel%2520potent%2520inhibitor%2520of%2520oncogenic%2520RET%2520mutants%2520associated%2520with%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3DE811%26epage%3DE819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x"> (</span><span class="NLM_issue">1–2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&issue=1%E2%80%932&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+potent+inhibitor+of+wild-type+and+drug-resistant+gatekeeper+mutant+RET+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0lgcw7PCTqCDYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520potent%2520inhibitor%2520of%2520wild-type%2520and%2520drug-resistant%2520gatekeeper%2520mutant%2520RET%2520kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Morgillo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orditura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vita, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciardiello, F.</span><span> </span><span class="NLM_article-title">Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e28841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e28841&author=F.+Morgilloauthor=E.+Martinelliauthor=T.+Troianiauthor=M.+Ordituraauthor=F.+De+Vitaauthor=F.+Ciardiello&title=Antitumor+activity+of+sorafenib+in+human+cancer+cell+lines+with+acquired+resistance+to+EGFR+and+VEGFR+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorgillo%26aufirst%3DF.%26aulast%3DMartinelli%26aufirst%3DE.%26aulast%3DTroiani%26aufirst%3DT.%26aulast%3DOrditura%26aufirst%3DM.%26aulast%3DDe%2BVita%26aufirst%3DF.%26aulast%3DCiardiello%26aufirst%3DF.%26atitle%3DAntitumor%2520activity%2520of%2520sorafenib%2520in%2520human%2520cancer%2520cell%2520lines%2520with%2520acquired%2520resistance%2520to%2520EGFR%2520and%2520VEGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De28841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magee, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Links, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstra, R. M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacke, C. M.</span><span> </span><span class="NLM_article-title">Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">29230</span><span class="NLM_x">–</span> <span class="NLM_lpage">29240</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=29230-29240&author=I.+Plaza-Menachoauthor=L.+Mologniauthor=E.+Salaauthor=C.+Gambacorti-Passeriniauthor=A.+I.+Mageeauthor=T.+P.+Linksauthor=R.+M.+W.+Hofstraauthor=D.+Barfordauthor=C.+M.+Isacke&title=Sorafenib+functions+to+potently+suppress+RET+tyrosine+kinase+activity+by+direct+enzymatic+inhibition+and+promoting+RET+lysosomal+degradation+independent+of+proteasomal+targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DSala%26aufirst%3DE.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMagee%26aufirst%3DA.%2BI.%26aulast%3DLinks%26aufirst%3DT.%2BP.%26aulast%3DHofstra%26aufirst%3DR.%2BM.%2BW.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DIsacke%26aufirst%3DC.%2BM.%26atitle%3DSorafenib%2520functions%2520to%2520potently%2520suppress%2520RET%2520tyrosine%2520kinase%2520activity%2520by%2520direct%2520enzymatic%2520inhibition%2520and%2520promoting%2520RET%2520lysosomal%2520degradation%2520independent%2520of%2520proteasomal%2520targeting%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D29230%26epage%3D29240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osgood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of motesanib in a medullary thyroid cancer model</span> <span class="citation_source-journal">J. Endocrinol. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=181-190&author=A.+Coxonauthor=J.+Breadyauthor=S.+Kaufmanauthor=J.+Estradaauthor=T.+Osgoodauthor=J.+Canonauthor=L.+Wangauthor=R.+Radinskyauthor=R.+Kendallauthor=P.+Hughesauthor=A.+Polverino&title=Anti-tumor+activity+of+motesanib+in+a+medullary+thyroid+cancer+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DEstrada%26aufirst%3DJ.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DPolverino%26aufirst%3DA.%26atitle%3DAnti-tumor%2520activity%2520of%2520motesanib%2520in%2520a%2520medullary%2520thyroid%2520cancer%2520model%26jtitle%3DJ.%2520Endocrinol.%2520Invest.%26date%3D2012%26volume%3D35%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span>Postgradute Cancer Research Symposium (at The University of Sydney, Nov<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>. <a href="http://sydney.edu.au/cancer-research/pdf/Final_Symposium_booklet.pdf" class="extLink">http://sydney.edu.au/cancer-research/pdf/Final_Symposium_booklet.pdf</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Postgradute+Cancer+Research+Symposium+%28at+The+University+of+Sydney%2C+Nov+2013%29+.+http%3A%2F%2Fsydney.edu.au%2Fcancer-research%2Fpdf%2FFinal_Symposium_booklet.pdf+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widemann, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuk, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitcomb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balis, F. M.</span><span> </span><span class="NLM_article-title">Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4239</span><span class="NLM_x">–</span> <span class="NLM_lpage">4248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1158%2F1078-0432.CCR-13-0071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23766359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4239-4248&author=E.+Foxauthor=B.+C.+Widemannauthor=M.+K.+Chukauthor=L.+J.+Marcusauthor=A.+Aikinauthor=P.+Whitcombauthor=M.+J.+Merinoauthor=M.+Lodishauthor=E.+Dombiauthor=S.+M.+Steinbergauthor=S.+A.+Wellsauthor=F.+M.+Balis&title=Vandetanib+in+children+and+adolescents+with+multiple+endocrine+neoplasia+type+2B+associated+medullary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma</span></div><div class="casAuthors">Fox, Elizabeth; Widemann, Brigitte C.; Chuk, Meredith K.; Marcus, Leigh; Aikin, Alberta; Whitcomb, Patricia O.; Merino, Maria J.; Lodish, Maya; Dombi, Eva; Steinberg, Seth M.; Wells, Samuel A.; Balis, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4239-4248</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET (REarranged during Transfection) proto-oncogene.  Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC.  Exptl. Design: We conducted a phase I/II trial of vandetanib for children (5-12 years) and adolescents (13-18 years) with MTC to define a recommended dose and assess antitumor activity.  The starting dose was 100 mg/m2 administered orally, once daily, continuously for 28-day treatment cycles.  The dose could be escalated to 150 mg/m2/d after two cycles.  Radiog. response to vandetanib was quantified using RECIST (v1.0), biomarker response was measured by comparing posttreatment serum calcitonin and carcinoembryonic antigen (CEA) levels to baseline, and a patient-reported outcome was used to assess clin. benefit.  Results: Sixteen patients with locally advanced or metastatic MTC received vandetanib for a median (range) 27 (2-52) cycles.  Eleven patients remain on protocol therapy.  Diarrhea was the primary dose-limiting toxicity.  In subjects with M918T RET germline mutations (n = 15) the confirmed objective partial response rate was 47% (exact 95% confidence intervals, 21%-75%).  Biomarker partial response was confirmed for calcitonin in 12 subjects and for CEA in 8 subjects.  Conclusion: Using an innovative trial design and selecting patients based on target gene expression, we conclude that vandetanib 100 mg/m2/d is a well-tolerated and highly active new treatment for children and adolescents with MEN2B and locally advanced or metastatic MTC.  Clin Cancer Res; 19(15); 4239-48. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptEqeEhvtU9rVg90H21EOLACvtfcHk0lg95sWR_GrMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zN&md5=738e0cdf62786fbc0db45df19cfd3eaa</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0071%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DE.%26aulast%3DWidemann%26aufirst%3DB.%2BC.%26aulast%3DChuk%26aufirst%3DM.%2BK.%26aulast%3DMarcus%26aufirst%3DL.%2BJ.%26aulast%3DAikin%26aufirst%3DA.%26aulast%3DWhitcomb%26aufirst%3DP.%26aulast%3DMerino%26aufirst%3DM.%2BJ.%26aulast%3DLodish%26aufirst%3DM.%26aulast%3DDombi%26aufirst%3DE.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DBalis%26aufirst%3DF.%2BM.%26atitle%3DVandetanib%2520in%2520children%2520and%2520adolescents%2520with%2520multiple%2520endocrine%2520neoplasia%2520type%25202B%2520associated%2520medullary%2520thyroid%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4239%26epage%3D4248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+genetic+discovery+of+targets+and+anti-targets+for+cancer+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0lg95sWR_GrMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520genetic%2520discovery%2520of%2520targets%2520and%2520anti-targets%2520for%2520cancer%2520polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D80%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+M%C3%BCllerauthor=P.+Sch%C3%B6ffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lg95sWR_GrMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%2BP.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer</span> <span class="citation_source-journal">Oral Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.oraloncology.2013.03.442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=23582411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1CgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=707-10&author=S.+I.+Sherman&title=Lessons+learned+and+questions+unanswered+from+use+of+multitargeted+kinase+inhibitors+in+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer</span></div><div class="casAuthors">Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Oral Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">707-710</span>CODEN:
                <span class="NLM_cas:coden">EJCCER</span>;
        ISSN:<span class="NLM_cas:issn">1368-8375</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To review studies of novel multitargeted kinase inhibitors studied in patients with medullary thyroid cancer (MTC).  Search of relevant refs. in PubMed and Google Scholar on "chemotherapy" and "medullary thyroid cancer".  Multitargeted kinase inhibitors have revolutionized the role of chemotherapy for progressive MTC, providing for the first time tolerable therapeutic options that can improve outcomes in patients with progressive disease.  Drugs thought to inhibit the RET kinase have advanced the furthest for this disease, but these agents also target the VEGF receptor along with other kinases that may be relevant to both beneficial and adverse effects.  Vandetanib improved progression-free survival from 19.3 to 30.5 mo compared with placebo in patients with metastatic disease, whereas cabozantinib improved progression-free survival from 4.0 mo to 11.2 mo in a population with more aggressive disease.  However, "cure" remains elusive, adverse events frequent, and exactly how such "targeted" agents actually function within MTC remains unclear.  New approaches to clin. trial design and the preclin. development of targeted agents may be required to optimize the combination of max. efficacy with minimal toxicity for patients with metastatic MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLAgDadLtuY7Vg90H21EOLACvtfcHk0ljmDlU6DVOirg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1CgtLc%253D&md5=1de31be1f7b2c85a0b1aba7c9210fd5d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.oraloncology.2013.03.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.oraloncology.2013.03.442%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DLessons%2520learned%2520and%2520questions%2520unanswered%2520from%2520use%2520of%2520multitargeted%2520kinase%2520inhibitors%2520in%2520medullary%2520thyroid%2520cancer%26jtitle%3DOral%2520Oncol.%26date%3D2013%26volume%3D49%26spage%3D707%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Houvras, Y.</span><span> </span><span class="NLM_article-title">Completing the arc: targeted inhibition of RET in medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2011.38.7639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22162569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFGrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=200-202&author=Y.+Houvras&title=Completing+the+arc%3A+targeted+inhibition+of+RET+in+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Completing the Arc: targeted inhibition of RET in medullary thyroid cancer</span></div><div class="casAuthors">Houvras, Yariv</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-202</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The research of Wells et al. (2012) entitled 'Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial' is reviewed with commentary and refs.  These authors present the results of the ZETA (Zactima Efficacy in Thyroid Cancer Assessment) trial, a phase III randomized, double-blind, placebo-controlled trial of vandetanib in patients with sporadic and hereditary medullary thyroid cancer (MTC).  Vandetanib (formerly ZD6474) is a small-mol. tyrosine kinase inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor (VEGFR) kinases.  In ZETA, patients with advanced MTC who were randomly assigned to treatment with vandetanib had significantly longer progression-free survival than those randomly assigned to treatment with placebo.  The results of the ZETA trial led the US Food and Drug Administration to approve vandetanib for treatment of symptomatic or progressive MTC earlier this year.  This is the first drug approved for MTC and the first TKI approved for any thyroid cancer indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU1hxYPMJuxbVg90H21EOLACvtfcHk0ljmDlU6DVOirg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFGrtr0%253D&md5=9a0cd65f556a9a573030eb4aea37ddf9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.38.7639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.38.7639%26sid%3Dliteratum%253Aachs%26aulast%3DHouvras%26aufirst%3DY.%26atitle%3DCompleting%2520the%2520arc%253A%2520targeted%2520inhibition%2520of%2520RET%2520in%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D200%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Wells, S. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dralle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasselli, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmuir, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span> </span><span class="NLM_article-title">Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2011.35.5040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=22025146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=134-141&author=S.+A.+Wellsauthor=B.+G.+Robinsonauthor=R.+F.+Gagelauthor=H.+Dralleauthor=J.+A.+Faginauthor=M.+Santoroauthor=E.+Baudinauthor=R.+Eliseiauthor=B.+Jarzabauthor=J.+R.+Vasselliauthor=J.+Readauthor=P.+Langmuirauthor=A.+J.+Ryanauthor=M.+J.+Schlumberger&title=Vandetanib+in+patients+with+locally+advanced+or+metastatic+medullary+thyroid+cancer%3A+a+randomized%2C+double-blind+phase+III+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</span></div><div class="casAuthors">Wells, Samuel A., Jr.; Robinson, Bruce G.; Gagel, Robert F.; Dralle, Henning; Fagin, James A.; Santoro, Massimo; Baudin, Eric; Elisei, Rossella; Jarzab, Barbara; Vasselli, James R.; Read, Jessica; Langmuir, Peter; Ryan, Anderson J.; Schlumberger, Martin I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC).  Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.  Patients and Methods Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo.  On objective disease progression, patients could elect to receive open-label vandetanib.  The primary end point was progression-free survival (PFS), detd. by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.  Results Between Dec. 2006 and Nov. 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100).  At data cutoff (July 2009; median follow-up, 24 mo), 37% of patients had progressed and 15% had died.  The study met its primary objective of PFS prolongation with vandetanib vs. placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001).  Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochem. response (P < .001).  Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65).  A final survival anal. will take place when 50% of the patients have died.  Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).  Conclusion Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnzd5Ld1n-AbVg90H21EOLACvtfcHk0ljmDlU6DVOirg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D&md5=99ea5fa9e2cd53b14f85b8a37e1e3c2b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5040%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DDralle%26aufirst%3DH.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DBaudin%26aufirst%3DE.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DVasselli%26aufirst%3DJ.%2BR.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DLangmuir%26aufirst%3DP.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26atitle%3DVandetanib%2520in%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520medullary%2520thyroid%2520cancer%253A%2520a%2520randomized%252C%2520double-blind%2520phase%2520III%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D134%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forastiere, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janisch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nauling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2660</span><span class="NLM_x">–</span> <span class="NLM_lpage">2666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1200%2FJCO.2010.32.4145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=21606412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2660-2666&author=R.+Kurzrockauthor=S.+I.+Shermanauthor=D.+W.+Ballauthor=A.+A.+Forastiereauthor=R.+B.+Cohenauthor=R.+Mehraauthor=D.+G.+Pfisterauthor=E.+E.+Cohenauthor=L.+Janischauthor=F.+Naulingauthor=D.+S.+Hongauthor=C.+S.+Ngauthor=L.+Yeauthor=R.+F.+Gagelauthor=J.+Fryeauthor=T.+M%C3%BCllerauthor=M.+J.+Ratainauthor=R.+Salgia&title=Activity+of+XL184+%28cabozantinib%29%2C+an+oral+tyrosine+kinase+inhibitor%2C+in+patients+with+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer</span></div><div class="casAuthors">Kurzrock, Razelle; Sherman, Steven I.; Ball, Douglas W.; Forastiere, Arlene A.; Cohen, Roger B.; Mehra, Ranee; Pfister, David G.; Cohen, Ezra E. W.; Janisch, Linda; Nauling, Forlisa; Hong, David S.; Ng, Chaan S.; Ye, Lei; Gagel, Robert F.; Frye, John; Muller, Thomas; Ratain, Mark J.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2660-2666</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclin. models.  Early observations of clin. benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article.  Patients and Methods: A phase I dose-escalation study of oral cabozantinib was conducted in patients with advanced solid tumors.  Primary end points included evaluation of safety, pharmacokinetics, and max.-tolerated dose (MTD) detn.  Addnl. end points included RECIST (Response Evaluation Criteria in Solid Tumors) response, pharmacodynamics, RET mutational status, and biomarker analyses.  Results: Eighty-five patients were enrolled, including 37 with MTC.  The MTD was 175 mg daily.  Dose-limiting toxicities were grade 3 palmar plantar erythrodysesthesia (PPE), mucositis, and AST, ALT, and lipase elevations and grade 2 mucositis that resulted in dose interruption and redn.  Ten (29%) of 35 patients with MTC with measurable disease had a confirmed partial response.  Overall, 18 patients experienced tumor shrinkage of 30% or more, including 17 (49%) of 35 patients with MTC with measurable disease.  Addnl., 15 (41%) of 37 patients with MTC had stable disease (SD) for at least 6 mo, resulting in SD for 6 mo or longer or confirmed partial response in 68% of patients with MTC.  Conclusion: Cabozantinib has an acceptable safety profile and is active in MTC.  Cabozantinib may provide clin. benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and RET.  A global phase III pivotal study in MTC is ongoing (ClinicalTrials.gov no. NCT00215605).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqsQ7UriHpu7Vg90H21EOLACvtfcHk0ljmDlU6DVOirg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbY%253D&md5=01614c45ab0e9fb3afff120e8e94e4bf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.32.4145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.32.4145%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26aulast%3DBall%26aufirst%3DD.%2BW.%26aulast%3DForastiere%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DPfister%26aufirst%3DD.%2BG.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DJanisch%26aufirst%3DL.%26aulast%3DNauling%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DNg%26aufirst%3DC.%2BS.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DFrye%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DActivity%2520of%2520XL184%2520%2528cabozantinib%2529%252C%2520an%2520oral%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2660%26epage%3D2666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Blencke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span> </span><span class="NLM_article-title">Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1016%2Fj.chembiol.2004.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=15157880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=691-701&author=S.+Blenckeauthor=B.+Zechauthor=O.+Engkvistauthor=Z.+Greffauthor=L.+Orfiauthor=Z.+Horvathauthor=G.+Keriauthor=A.+Ullrichauthor=H.+Daub&title=Characterization+of+a+conserved+structural+determinant+controlling+protein+kinase+sensitivity+to+selective+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors</span></div><div class="casAuthors">Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Some protein kinases are known to acquire resistance to selective small mol. inhibitors upon mutation of a conserved threonine at the ATP binding site to a larger residue.  Here, we performed a comprehensive mutational anal. of this structural element and detd. the cellular sensitivities of several disease-relevant tyrosine kinases against various inhibitors.  Mutant kinases possessing a larger side chain at the crit. site showed resistance to most compds. tested, such as ZD1839, PP1, AG1296, STI571, and a pyrido[2,3-d]pyrimidine inhibitor.  In contrast, indolinones affected both wild-type and mutant kinases with similar potencies.  Resistant mutants were established for pharmacol. anal. of βPDGF receptor-mediated signaling and allowed the generation of a drug-inducible system of cellular Src kinase activity.  Our data establish a conserved structural determinant of protein kinase sensitivity relevant for both signal transduction research and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWLToAufPZDbVg90H21EOLACvtfcHk0lixY7KbppsUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2qsro%253D&md5=3224f7453efd9b60f5102e300d195aa0</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DBlencke%26aufirst%3DS.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DDaub%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520a%2520conserved%2520structural%2520determinant%2520controlling%2520protein%2520kinase%2520sensitivity%2520to%2520selective%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D691%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witucki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=1219-1226&author=Y.+Liuauthor=K.+Shahauthor=F.+Yangauthor=L.+Wituckiauthor=K.+M.+Shokat&title=A+molecular+gate+which+controls+unnatural+ATP+analogue+recognition+by+the+tyrosine+kinase+v-Src"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DWitucki%26aufirst%3DL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520molecular%2520gate%2520which%2520controls%2520unnatural%2520ATP%2520analogue%2520recognition%2520by%2520the%2520tyrosine%2520kinase%2520v-Src%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1998%26volume%3D6%26spage%3D1219%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Bishop, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubersax, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petsch, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheos, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blethrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsien, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A chemical switch for inhibitor-sensitive alleles of any protein kinase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2F35030148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=11014197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2ntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=395-401&author=A.+C.+Bishopauthor=J.+A.+Ubersaxauthor=D.+T.+Petschauthor=D.+P.+Matheosauthor=N.+S.+Grayauthor=J.+Blethrowauthor=E.+Shimizuauthor=J.+Z.+Tsienauthor=P.+G.+Schultzauthor=M.+D.+Roseauthor=J.+L.+Woodauthor=D.+O.+Morganauthor=K.+M.+Shokat&title=A+chemical+switch+for+inhibitor-sensitive+alleles+of+any+protein+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A chemical switch for inhibitor-sensitive alleles of any protein kinase</span></div><div class="casAuthors">Bishop, Anthony C.; Ubersax, Jeffrey A.; Petsch, Dejah T.; Matheos, Dina P.; Gray, Nathanael S.; Blethrow, Justin; Shimizu, Eiji; Tsien, Joe Z.; Schultz, Peter G.; Rose, Mark D.; Wood, John L.; Morgan, David O.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6802</span>),
    <span class="NLM_cas:pages">395-401</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases have proved to be largely resistant to the design of highly specific inhibitors, even with the aid of combinatorial chem.  The lack of these reagents has complicated efforts to assign specific signaling roles to individual kinases.  Here we describe a chem. genetic strategy for sensitizing protein kinases to cell-permeable mols. that do not inhibit wild-type kinases.  From two inhibitor scaffolds, we have identified potent and selective inhibitors for sensitized kinases from five distinct subfamilies.  Tyrosine and serine/threonine kinases are equally amenable to this approach.  We have analyzed a budding yeast strain carrying an inhibitor-sensitive form of the cyclin-dependent kinase Cdc28 (CDK1) in place of the wild-type protein.  Specific inhibition of Cdc28 in vivo caused a pre-mitotic cell-cycle arrest that is distinct from the G1 arrest typically obsd. in temp.-sensitive cdc28 mutants.  The mutation that confers inhibitor-sensitivity is easily identifiable from primary sequence alignments.  Thus, this approach can be used to systematically generate conditional alleles of protein kinases, allowing for rapid functional characterization of members of this important gene family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqipYQXO52a6rVg90H21EOLACvtfcHk0lhGX0hTF9patg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2ntL4%253D&md5=736782d1116a86dfc0dd6ab9a9aeec0a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2F35030148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35030148%26sid%3Dliteratum%253Aachs%26aulast%3DBishop%26aufirst%3DA.%2BC.%26aulast%3DUbersax%26aufirst%3DJ.%2BA.%26aulast%3DPetsch%26aufirst%3DD.%2BT.%26aulast%3DMatheos%26aufirst%3DD.%2BP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DBlethrow%26aufirst%3DJ.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DTsien%26aufirst%3DJ.%2BZ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DRose%26aufirst%3DM.%2BD.%26aulast%3DWood%26aufirst%3DJ.%2BL.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520chemical%2520switch%2520for%2520inhibitor-sensitive%2520alleles%2520of%2520any%2520protein%2520kinase%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D395%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span> </span><span class="NLM_article-title">ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S6</span><span class="NLM_x">–</span> <span class="NLM_lpage">S13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=S6-S13&issue=Suppl.+1&author=A.+J.+Ryanauthor=S.+R.+Wedge&title=ZD6474%E2%80%94a+novel+inhibitor+of+VEGFR+and+EGFR+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26atitle%3DZD6474%25E2%2580%2594a%2520novel%2520inhibitor%2520of%2520VEGFR%2520and%2520EGFR%2520tyrosine%2520kinase%2520activity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26issue%3DSuppl.%25201%26spage%3DS6%26epage%3DS13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaganti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6056</span><span class="NLM_x">–</span> <span class="NLM_lpage">6063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6056-6063&author=F.+Carlomagnoauthor=T.+Guitaauthor=S.+Anagantiauthor=G.+Vecchioauthor=A.+Fuscoauthor=A.+J.+Ryanauthor=M.+Billaudauthor=M.+Santoro&title=Disease+associated+mutations+at+valine+804+in+the+RET+receptor+tyrosine+kinase+confer+resistance+to+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DGuita%26aufirst%3DT.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DDisease%2520associated%2520mutations%2520at%2520valine%2520804%2520in%2520the%2520RET%2520receptor%2520tyrosine%2520kinase%2520confer%2520resistance%2520to%2520selective%2520kinase%2520inhibitors%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6056%26epage%3D6063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer</span> <span class="citation_source-journal">J. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1179%2Fjoc.2004.16.Supplement-1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=15693160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFantb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=49-51&issue=Suppl.+1&author=F.+Carlomagnoauthor=M.+Santoro&title=Identification+of+RET+kinase+inhibitors+as+potential+new+treatment+for+sporadic+and+inherited+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer</span></div><div class="casAuthors">Carlomagno, F.; Santoro, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemotherapy (Firenze, Italy)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">49-51</span>CODEN:
                <span class="NLM_cas:coden">JCHEEU</span>;
        ISSN:<span class="NLM_cas:issn">1120-009X</span>.
    
            (<span class="NLM_cas:orgname">E.S.I.F.T. srl</span>)
        </div><div class="casAbstract">A review.  The RET gene is frequently mutated in papillary thyroid carcinoma and in medullary thyroid carcinoma.  We have identified three different anti-RET drugs: two pyrazolo-pyrimidines, PP1 and PP2 and an anilinoquinazoline, ZD6474 (AstraZeneca).  These compds. are able to inhibit RET kinase activity in vitro (IC50 dose 100 nM) and in vivo and they can prevent RET mediated transformation.  Finally, mutation of RET V804 to methionine or leucine, found in MTC patients, induces resistance to the three drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBTHWsZ79LB7Vg90H21EOLACvtfcHk0lhGX0hTF9patg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFantb4%253D&md5=7ea950a62eb1a85019f6939616064eba</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1179%2Fjoc.2004.16.Supplement-1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1179%252Fjoc.2004.16.Supplement-1.49%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520RET%2520kinase%2520inhibitors%2520as%2520potential%2520new%2520treatment%2520for%2520sporadic%2520and%2520inherited%2520thyroid%2520cancer%26jtitle%3DJ.%2520Chemother.%26date%3D2004%26volume%3D16%26issue%3DSuppl.%25201%26spage%3D49%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Dinér, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alao, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Söderlund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunnerhagen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grøtli, M.</span><span> </span><span class="NLM_article-title">Preparation of 3-substituted-1-isopropyl-1<i>H</i>-pyrazole[3,4-<i>d</i>]pyrimidin-4-amines as RET kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4876</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003944" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4872-4876&author=P.+Din%C3%A9rauthor=J.+P.+Alaoauthor=J.+S%C3%B6derlundauthor=P.+Sunnerhagenauthor=M.+Gr%C3%B8tli&title=Preparation+of+3-substituted-1-isopropyl-1H-pyrazole%5B3%2C4-d%5Dpyrimidin-4-amines+as+RET+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm3003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003944%26sid%3Dliteratum%253Aachs%26aulast%3DDin%25C3%25A9r%26aufirst%3DP.%26aulast%3DAlao%26aufirst%3DJ.%2BP.%26aulast%3DS%25C3%25B6derlund%26aufirst%3DJ.%26aulast%3DSunnerhagen%26aufirst%3DP.%26aulast%3DGr%25C3%25B8tli%26aufirst%3DM.%26atitle%3DPreparation%2520of%25203-substituted-1-isopropyl-1H-pyrazole%255B3%252C4-d%255Dpyrimidin-4-amines%2520as%2520RET%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4872%26epage%3D4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Grieco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlingieri, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melillo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donghi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongarzone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Porta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span> </span><span class="NLM_article-title">PTC is a novel rearranged form of the <i>RET</i> proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">563</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1990&pages=557-563&author=M.+Griecoauthor=M.+Santoroauthor=M.+T.+Berlingieriauthor=R.+M.+Melilloauthor=R.+Donghiauthor=I.+Bongarzoneauthor=M.+A.+Pierottiauthor=G.+Della+Portaauthor=A.+Fuscoauthor=G.+Vecchio&title=PTC+is+a+novel+rearranged+form+of+the+RET+proto-oncogene+and+is+frequently+detected+in+vivo+in+human+thyroid+papillary+carcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrieco%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DBerlingieri%26aufirst%3DM.%2BT.%26aulast%3DMelillo%26aufirst%3DR.%2BM.%26aulast%3DDonghi%26aufirst%3DR.%26aulast%3DBongarzone%26aufirst%3DI.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DDella%2BPorta%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DVecchio%26aufirst%3DG.%26atitle%3DPTC%2520is%2520a%2520novel%2520rearranged%2520form%2520of%2520the%2520RET%2520proto-oncogene%2520and%2520is%2520frequently%2520detected%2520in%2520vivo%2520in%2520human%2520thyroid%2520papillary%2520carcinomas%26jtitle%3DCell%26date%3D1990%26volume%3D60%26spage%3D557%26epage%3D563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">ALKoma: a cancer subtype with a shared target</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=495-502&author=H.+Mano&title=ALKoma%3A+a+cancer+subtype+with+a+shared+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DALKoma%253A%2520a%2520cancer%2520subtype%2520with%2520a%2520shared%2520target%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D495%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgjjMQmoVLwTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm501464c&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm501464c&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm501464c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lgjjMQmoVLwTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Kohno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakaoku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span> </span><span class="NLM_article-title">RET fusion gene: translation to personalized lung cancer therapy</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=1396-1400&author=T.+Kohnoauthor=K.+Tsutaauthor=K.+Tsuchiharaauthor=T.+Nakaokuauthor=K.+Yohauthor=K.+Goto&title=RET+fusion+gene%3A+translation+to+personalized+lung+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DTsuchihara%26aufirst%3DK.%26aulast%3DNakaoku%26aufirst%3DT.%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26atitle%3DRET%2520fusion%2520gene%253A%2520translation%2520to%2520personalized%2520lung%2520cancer%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D104%26spage%3D1396%26epage%3D1400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span>Overview of Targeted Therapies for Cancer. <a href="http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/" class="extLink">http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/</a> (accessed Jan 2,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Overview+of+Targeted+Therapies+for+Cancer.+http%3A%2F%2Fwww.mycancergenome.org%2Fcontent%2Fother%2Fmolecular-medicine%2Foverview-of-targeted-therapies-for-cancer%2F+%28accessed+Jan+2%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501464c&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-9%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm501464c%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501464c" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aac013bcc3cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
